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ABSTRACT 
 
The transmembrane subunit (gp41) of the envelope glycoprotein of HIV-1 
associates noncovalently with the surface subunit (gp120) and together they play 
essential roles in viral mucosal transmission and infection of target cells. The membrane 
proximal region (MPR, residues 649-683) of gp41 is highly conserved and contains 
epitopes of broadly neutralizing antibodies. The transmembrane (TM) domain (residues 
684-705) of gp41 not only anchors the envelope glycoprotein complex in the viral 
membrane but also dynamically affects the interactions of the MPR with the membrane. 
While high-resolution X-ray structures of some segments of the MPR were solved in the 
past, they represent the pre-fusion and post-fusion conformations, most of which could 
not react with the broadly neutralizing antibodies 2F5 and 4E10. Structural information 
on the TM domain of gp41 is scant and at low resolution. 
This thesis describes the structural studies of MPR-TM (residues 649-705) of HIV-
1 gp41 by X-ray crystallography. MPR-TM was fused with different fusion proteins to 
improve the membrane protein overexpression. The expression level of MPR-TM was 
improved by fusion to the C-terminus of the Mistic protein, yielding ∼1 mg of pure 
MPR-TM protein per liter cell culture. The fusion partner Mistic was removed for final 
crystallization. The isolated MPR-TM protein was biophysically characterized and is a 
monodisperse candidate for crystallization. However, no crystal with diffraction quality 
was obtained even after extensive crystallization screens. A novel construct was designed 
to overexpress MPR-TM as a maltose binding protein (MBP) fusion. About 60 mg of 
MBP/MPR-TM recombinant protein was obtained from 1 liter of cell culture. Crystals of 
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MBP/MPR-TM recombinant protein could not be obtained when MBP and MPR-TM 
were separated by a 42 amino acid (aa)-long linker but were obtained after changing the 
linker to three alanine residues. The crystals diffracted to 2.5 Å after crystallization 
optimization. Further analysis of the diffraction data indicated that the crystals are 
twinned. The final structure demonstrated that MBP crystallized as a dimer of trimers, 
but the electron density did not extend beyond the linker region. We determined by SDS-
PAGE and MALDI-TOF MS that the crystals contained MBP only. The MPR-TM of 
gp41 might be cleaved during or after the process of crystallization. Comparison of the 
MBP trimer reported here with published trimeric MBP fusion structures indicated that 
MBP might form such a trimeric conformation under the effect of MPR-TM. 
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CHAPTER 1 
INTRODUCTION 
1.1 Current Status Of HIV Infections Worldwide 
The human immunodeficiency virus (HIV), the virus that causes acquired immune 
deficiency syndrome (AIDS), has become one of the world’s most serious health 
problems. AIDS was first reported in 1981 (Patrick et al., 2013). According to the World 
Health Organization (WHO), almost 75 million people have been infected with HIV virus 
and about 36 million people have died of HIV since the beginning of the epidemic. An 
estimation of 35 million people are living with HIV globally (The Gap report - unaids, 
2013). However, there is no effective vaccine against HIV-1. The HIV-1 virus has 
evolved multiple strategies to escape the antibody binding (Johnson and Desrosiers, 
2002). The envelope glycoprotein (Env) glycoprotein of HIV-1 is heavily glycosylated, 
and the poorly immunogenic glycans inhibit antibody access to the underlying peptide 
(Burton et al., 2004). Trimerization of Env makes epitopes in Env less accessible to 
antibodies compared with monomeric subunit (Burton et al., 2004). Conformational 
change of Env during virus fusion with target cell makes epitopes in Env only accessible 
in the intermediate stage. High mutation rate of HIV due to low fidelity of the reverse 
transcriptase (RT) is another important reason why no vaccine exists so far (Preston et al., 
1988). These strategies make the development of vaccine against HIV-1 more difficult. 
1.2 The Env of HIV-1 
The Env of HIV-1 plays an essential role for virus attachment and fusion with 
target cells and is a primary target for vaccine development (Hughson, 1997). The HIV-1 
glycoprotein is initially expressed as a precursor form gp160, which is then 
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proteolytically cleaved into two non-covalently associated subunits: gp120 and gp41 
(Decroly et al., 1994). Gp120, a surface subunit, is responsible for recognizing and 
binding to cell surface receptors CD4 and a coreceptor, usually CCR5 or CXCR4 (Broder 
and Dimitrov, 1996; Moore et al., 1997), while gp41, a transmembrane subunit, mediates 
fusion between viral and cellular membranes through its own conformational change 
(Chan and Kim, 1998). At the surface of the virus, HIV-1 Env oligomerize into a trimer 
of heterodimers consisting of gp120 and gp41, in which gp120 forms a cap covering most 
of the gp41(Chan et al., 1997; Weissenhorn et al., 1997). 
The Env of HIV-1 gp41 consists of an ectodomain (residues 512–683), a 
transmembrane domain (residues 684–705), and a cytoplasmic domain (residues 706–
856) (Weiss, 2003; Checkley et al., 2011). Biophysical and structural studies delineate 
further distinct structural and functional features within the ectodomain of gp41 (Fig. 
1.1). The very N-terminus of gp41 is a hydrophobic glycine-rich fusion peptide (FP, 
residues 512-527), which is exposed and inserted into the target cell membrane at an 
early step of the fusion process. The N-terminal heptad repeat (NHR or HR1, residues 
540-590) is adjacent to the FP, while the C-terminal heptad repeat (CHR or HR2, 
residues 628-661) precedes the membrane proximal external region (MPER, residues 
662-682) and transmembrane (TM, residues 684-705) domain. The membrane proximal 
region (MPR) with residues 649 to 683 is composed of part of CHR (residues 647 to 661) 
and the whole MPER (residues 662 to 683). MPR-TM is among the most highly 
conserved regions in the HIV-1 Env and contains epitopes for the neutralizing 
monoclonal antibodies (mAbs) 2F5 (Purtscher et al., 1994), 4E10 (Zwick et al., 2001) 
and 10E8 (Huang et al., 2012).  
	   3 
FPPR FP NHR CHR TM MPER CP 
512         527        540                                                 590                                  628              649             661                  684                 705        856          
    SQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSMV 
2F5 4E10, 10E8 
MPR 
S−S 
 
Fig. 1.1 Schematic diagram of the sequence of HIV-1 gp41. FP (residues 512-527): 
fusion peptide; FPRR (residues 528-539): fusion peptide proximal region; NHR (residues 
540-590): N-terminal heptad repeat region; S-S: a disulfide linkage; CHR (residues 628-
661): C-terminal heptad repeat region; MPER (residues 662-683): membrane proximal 
external region; MPR (residues 649-683): membrane proximal region; TM (residues 684-
705): transmembrane domain; CP (residues 706-856): cytoplasmic domain. 2F5, 4E10 
and 10E8 are epitopes for three broadly neutralizing mAbs. 
 
1.3 Current Model of HIV-1 Membrane Fusion 
One current model for HIV-1 viral membrane fusion is shown in Fig. 1.2A (Eckert 
and Kim, 2001). The conformation of gp41 undergoes at least three different stages 
during this process: native trimer, pre-hairpin intermediate and postfusion six-helix 
bundle. In the native stage, Env is a trimer of heterodimers consisting of gp120 and gp41. 
The FP and NHR (or HR1) are buried in the interior of gp120. Binding of gp120 to the 
target cell receptor CD4 and a coreceptor CCR5 or CXCR4 triggers the conformational 
change of the Env. FP and NHR (or HR1) are exposed and extended into the target cell 
membrane, which leads to the prehairpin intermediate of gp41. The postfusion 
conformation of gp41 is a trimer of hairpin formed by antiparallel association of NHR (or 
HR1) and CHR (or HR2). Three NHRs form an interior, parallel coiled-coil trimer, while 
three CHRs pack in an antiparallel manner on the surface of NHRs. This rearrangement 
results in membrane apposition.  
The fusion process has provided a target for anti-HIV-1 drug therapy. Some HIV-1 
fusion inhibitors, C-peptides (Wild et al., 1992; Jiang et al., 1993; Wild et al., 1994; Lu et 
al., 1995; Wild et al., 1995) for example, are synthetic peptides derived from the CHR, 
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which can bind the NHR of gp41 during the intermediate stage and therefore interrupt the 
fusion process by preventing the post-fusion stage (Eckert and Kim, 2001). Cyclic D 
peptides, which target a hydrophobic picket on the NHR of gp41, inhibit HIV-1 entry in 
the same manner (Eckert et al., 1999; Cole and Garsky, 2001).  In addition, N-peptides, 
which are synthetic peptides derived from the NHR of gp41, can also inhibit HIV-1 entry 
(Fig. 1.2B) (Wild et al., 1992; Lu et al., 1995). There are two possible mechanisms. First, 
synthetic N-peptides may target an exposed region in the CHR of gp41. Second, synthetic 
N-peptides may intercalate with NHR of gp41, forming a heterotrimeric coiled coil and 
inhibiting the formation of NHR coiled coil (Wild et al., 1992). 
 
Fig. 1.2 (A) One of the current models of HIV-1 membrane fusion and its inhibition. (B) 
Representation of two possible mechanisms for synthetic N-peptides inhibitory activity as 
proposed by Eckert and Kim (Eckert and Kim, 2001). (©2001 by Proceeding of the 
National Academy of Sciences of the USA) 
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1.4 Accessibility of Epitopes on MPR During Viral Membrane Fusion 
Although there are three broadly neutralizing mAbs (2F5, 4E10 and 10E8) 
recognizing the MPR of HIV-1 gp41, the epitopes are not always accessible for Ab 
binding.  Frey et al. reported that mAbs 2F5 and 4E10 were not able to bind the native 
trimer of gp140 (the ectodomain of the precursor gp160), which indicated that epitopes of 
2F5 and 4E10 are either shielded or in a nonantigenic conformation on the native gp140 
trimer (Frey et al., 2008). They also detected that postfusion gp41 binds the 2F5 Fab very 
weekly (KD ≈ 1.4 µM). Therefore, the 2F5 epitope in postfusion gp41 does not have the 
optimal binding conformation. Frey and co-workers have designed an intermediate gp41 
by adding an extra HR2 at the N-terminus of gp41 ectodomain (see gp41-inter in Fig. 
1.3). The extra HR2 at the N-terminus interacted with HR1 and formed a six-helix bundle 
with HR1, which leaves the real HR2 at the C-terminus and MPER in the coiled coil 
conformation, mimicking the prehairpin intermediate during viral membrane fusion. The 
Fab fragment of mAb 2F5 and the single-chain Fv fragment of mAb 4E10 bind gp41-
inter proteins (schematic representation shown in Fig. 1.3) very tightly (KD < 10 nM). It 
is therefore concluded by Frey et al. that the epitopes of 2F5 and 4E10 are only exposed 
on a form designed to mimic a prehairpin intermediate state during viral membrane 
fusion. 
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Fig. 1.3 Schematic representation of HIV-1 Env. Gp160, the full length precursor; gp140, 
uncleaved ectodomain of gp160 with a C-terminal His tag; gp140-Fd, uncleaved 
ectodomain of gp160 with a trimerization tag and a C-terminal His tag; gp41-inter, gp41 
in the prehairpin intermediate conformation trapped by an N-terminal HR2 peptide and a 
C-terminal foldon tag; gp41-post, gp41 in the six-helix conformation with partial MPER 
(Frey et al., 2008). (©2008 by The National Academy of Sciences of the USA) 
 
1.5 Current Structural Models of HIV-1 Gp41 Solved in Different Conformations 
Structures of trimeric MPER have been solved in the pre-fusion conformation 
(Pancera et al., 2014) and post-fusion “six-helix bundle” state (Buzon et al., 2010), 
respectively. However, both of them could not be recognized by the broadly neutralizing 
antibodies 2F5 or 4E10, which is consistent to Frey et al’s conclusion discussed 
previously. Another structure of trimeric MPER has been solved in the postfusion state (a 
six-helix bundle) containing a shortened NHR (HR1) region, which left MPER accessible 
to the 2F5 antibodies (Shi et al., 2010). More recently, Reardon et al. reported a trimeric 
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MPER structure solved by NMR spectroscopy in a putative pre-fusion intermediate state 
(a three-helix bundle) (Reardon et al., 2014). In their structure, the N termini of the 
MPER helices are closely associated with each other while the C termini gradually 
separate, which leaves space for antibody binding. However, in their construct, MPER 
was fused to the C terminus of a 27-residue trimerization domain from bacteriophage T4 
fibritin (the foldon domain). Although Reardon et al. reported that MPER was linked to 
the foldon motif through a flexible linker GSSG, which is intended to minimize the effect 
of the structured trimerization motif on the conformation and dynamics of MPER, it is 
still not experimentally confirmed that MPER forms a trimer in the pre-fusion 
intermediate form without the effect of a trimerization motif.  
Mao et al. reported a 6-Å structure of the membrane-bound HIV-1 envelope 
glycoprotein trimer in its uncleaved state by using cryo-electron microscopy (EM), which 
included the TM domain of gp41 (Mao et al., 2013). Their low-resolution structural 
model proposed that the TM domain of gp41 might form a left-handed three α-helical 
coiled coil. This is the only structural information of the TM domain of HIV-1 gp41 
reported so far. The atomic structure of the gp41 TM domain is still unknown. 
1.6 Crystallization of Membrane Proteins  
Crystallization of membrane proteins is very challenging. With more than 100,000 
protein structures in Protein Data Bank (PDB), there are only 504 unique structures of 
membrane proteins deposited so far (Berman et al., 2000; Berman et al., 2002). Each step 
in the process of crystallization of membrane proteins can be more difficult than that of 
soluble proteins. First, it is difficult to produce large amounts of correctly folded 
membrane proteins. The limited membrane surface area in the expression cell line may 
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not only limit the total amount of properly-folded recombinant proteins, but also may 
have cytotoxic consequences by competitively reducing the production of vital host 
membrane proteins or by negatively affecting membrane physiology (Roosild et al., 
2005). Even if the target membrane proteins are expressed in large amounts, it cannot be 
guaranteed that the over-expressed proteins are correctly folded in the membrane. When 
expressed in E. coli, the overexpressed membrane proteins form aggregates within the 
cell in form of inclusion bodies (Ni da et al., 2011). As proteins in inclusion bodies are 
normally mistakenly folded or unfolded, they cannot be directly used for crystallization. 
Refolding of membrane proteins from inclusion bodies to reconstitute properties 
appropriate to their native counterparts is complicated (Rogl et al., 1998; Ni da et al., 
2011) but has been achieved in some cases (Kiefer et al., 1999; Janovick et al., 2007; 
Dockter et al., 2009). Second, purification of membrane proteins is particularly delicate. 
The initial step in membrane protein purification is to extract and solubilize membrane 
proteins in a correctly folded conformation from the membrane. Detergents need to be 
screened to extract the target membrane protein in their native state. Special care needs to 
be taken during the concentration step to avoid the concentration of detergents, which 
may denature the protein (Wiener, 2004). In addition, the detergent/protein complex 
needs to be monodisperse prior to its entry into the crystallization pipeline (Prive, 2007; 
Prince and Jia, 2013). However, fulfillment of all these critical criteria did not necessarily 
yield diffracting crystals. No wonder some scientists often say crystallization is more of 
an art than a science (Desiraju, 2001). 
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1.7 Background on Recombinant Protein Expression of the Transmembrane and 
Membrane Proximal Domains of HIV-1 Gp41  
In this dissertation, MPR-TM is expressed with different fusion proteins to help 
with the expression, purification and structural studies by X-ray crystallography.  
The use of P8CBD (P8 is the coat protein of M13 bacteriophage and CBD is a 
chitin binding domain from Bacillus circulans) was initially tested as a protein fusion 
partner, which can promote the over-expression of membrane proteins by utilizing the co-
translational Signal Recognition Particle (SRP) pathway to target heterogonous proteins 
to the E. coli inner membrane (Luo et al., 2009). The P8CBD fusion partner begins with 
the M13 bacteriophage coat protein P8, which was designed for optimal membrane 
targeting. P8 is followed by a chitin binding domain (CBD) from Bacillus circulans, 
which serves as an affinity tag for future purification. However, use of the P8CBD 
expression vector resulted in extremely poor accumulation of properly targeted MPR-TM. 
Mistic, a Bacillus subtilis integral membrane protein that autonomously folds into 
the membrane, was fused to the N-terminus of MPR-TM to improve the expression yield 
(Gong et al., 2014). About 1 mg of monodisperse MPR-TM protein was obtained from 1 
liter of cell culture, but no crystals were obtained even after extensive crystallization 
screens. This work is discussed in Chapter 2.   
A novel construct was designed to overexpress MPR-TM as a maltose binding 
protein (MBP) fusion. MBP is a commonly used fusion partner, capable of improving the 
solubility and expression level of the target protein (Kapust and Waugh, 1999; Kobe et al., 
1999; Do et al., 2014; Nguyen et al., 2014; Raran-Kurussi and Waugh, 2014). The 
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expression, purification, biophysical characterization and crystallization of MPR-TM as 
MBP fusion protein are discussed in Chapter 3 and 4. 
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CHAPTER 2 
RECOMBINANT EXPRESSION, PURIFICATION, AND BIOPHYSICAL 
CHARACTERIZATION OF THE TRANSMEMBRANE AND MEMBRANE 
PROXIMAL DOMAINS OF HIV-1 GP41 AS MISTIC FUSION PROTEIN 
Text and Figures in this chapter were reprinted with permission from Gong, Z., Kessans, 
S. A., Song, L., Dorner, K., Lee, H. H., Meador, L. R., LaBaer, J., Hogue, B. G., Mor, T. 
S., and Fromme, P. (2014) Recombinant expression, purification and biophysical 
characterization of the transmembrane and membrane proximal domains of HIV-1 gp41, 
Protein Sci. It has been included in the dissertation with permission from the journal. 
2.1 Abstract 
The transmembrane subunit (gp41) of the envelope glycoprotein of HIV-1 
associates noncovalently with the surface subunit (gp120) and together they play essential 
roles in viral mucosal transmission and infection of target cells. The membrane proximal 
region (MPR) of gp41 is highly conserved and contains epitopes of broadly neutralizing 
antibodies. The transmembrane (TM) domain of gp41 not only anchors the envelope 
glycoprotein complex in the viral membrane but also dynamically affects the interactions 
of the MPR with the membrane. While high-resolution X-ray structures of some 
segments of the MPR were solved in the past, they represent the post-fusion forms. 
Structural information on the TM domain of gp41 is scant and at low resolution. Here we 
describe the design, expression and purification of a protein construct that includes MPR 
and the transmembrane domain of gp41 (MPR-TMTEV-6His), which reacts with the broadly 
neutralizing antibodies 2F5 and 4E10 and thereby may represent an immunologically 
relevant conformation mimicking a prehairpin intermediate of gp41. The expression level 
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of MPR-TMTEV-6His was improved by fusion to the C-terminus of Mistic protein, yielding ∼1 mg of pure protein per liter. The isolated MPR-TMTEV-6His protein was biophysically 
characterized and is a monodisperse candidate for crystallization. This work will enable 
further investigation into the structure of MPR-TMTEV-6His, which will be important for 
the structure-based design of a mucosal vaccine against HIV-1. 
2.2 Introduction 
The envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) 
plays essential roles in virus attachment and fusion with target cells (Hughson, 1997) and 
is also a primary target for vaccine design (Burton et al., 2004). It is a complex consisting 
of two non-covalently associated subunits that are cleaved off their precursor polyprotein 
to form the surface (gp120) and the transmembrane subunit (gp41) (Checkley et al., 
2011). The transmembrane anchor, gp41, consists of an ectodomain (Residues 512-683, 
Fig. 2.1), a transmembrane domain (Residues 684-705), and a cytoplasmic domain 
(Residues 706-856) (Weiss, 2003; Checkley et al., 2011). Biophysical and structural 
studies delineate further distinct structural and functional features within the ectodomain 
of gp41 (Fig. 2.1) including the N-terminal and C-terminal heptad repeat regions (NHR 
and CHR) (Chan et al., 1997; Weissenhorn et al., 1997; Checkley et al., 2011) that are 
flanked by the fusion peptide (FP) and the fusion peptide proximal region (FPPR) on one 
side, and the membrane proximal external region (MPER) on the other side.  
Target-cell infection by HIV-1 is initiated when gp120 binds to its primary receptor 
CD4 and coreceptor, usually CCR5 or CXCR4 (Broder and Dimitrov, 1996; Moore et al., 
1997). The exact mechanism leading to virus entry is still not known. A current model 
proposes that following binding of gp120 to its receptors, the gp41 subunit is exposed, 
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triggering drastic sequential changes in its conformation culminating in fusion between 
the viral envelope and the target cell’s plasma membrane (Gallo et al., 2003; Melikyan, 
2008; Ashkenazi and Shai, 2011). According to this model, NHR and CHR of gp41 are 
partially shielded by gp120, and switch to an extended conformation upon the latter’s 
removal to allow insertion of the FP into the target cell’s membrane (Liu et al., 2009; 
Buzon et al., 2010; Shi et al., 2010). After the fusion of the juxtaposed viral and cellular 
membranes, gp41’s core regains the 6-helical bundle conformation of post-fusion 
complex (Chan and Kim, 1998).  
 
Figure 2.1. Schematic diagram of HIV-1 gp41. FP (Residues 512-527): fusion peptide; 
FPRR (Residues 528-539): fusion peptide proximal region; NHR (Residues 540-590): N-
terminal heptad repeat region; S-S: a disulfide linkage; CHR (Residues 628-661): C-
terminal heptad repeat region; MPER (Residues 662-683): membrane proximal external 
region; MPR (Residues 649-683): membrane proximal region; TM (Residues 684-705): 
transmembrane domain; CTD (Residues 706-856): cytoplasmic domain. 2F5, 4E10 and 
10E8 are epitopes for three broadly neutralizing mAbs. 
 
In addition to its well-recognized role in infection of target CD4+ cells, gp41 is 
instrumental during early steps in various processes leading to mucosal transmission of 
the virus (Wu, 2008; Bomsel et al., 2011; Shen et al., 2011; Puryear and Gummuluru, 
2013). The virus is utilizing several routes to cross epithelial surfaces including capture 
by dendritic and Langerhans cells prevailing in pluristratified epithelia and transcytosis 
that is particularly important in simple epithelia (Ganor and Bomsel, 2011).  
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A key player in the transcytosis process is a region of the gp41 corresponding to 
residues 649-683, which includes the MPER and part of the CHR and will be referred to 
here in correspondence with Matoba et al. (Matoba et al., 2006) as “MPR”. Transcytosis 
is initiated when the MPR binds to the glycosphingolipid galactosyl ceramide (GalCer) 
and the co-receptor CCR5 (Alfsen and Bomsel, 2002; Meng et al., 2002; Puryear and 
Gummuluru, 2013). GalCer is enriched at the apical membrane of epithelial cells (Simons 
and van Meer, 1988) and is involved in the establishment of lipid rafts (Brown and 
London, 1998; Rietveld and Simons, 1998), which are proposed to act as platforms for 
HIV-1 entry (Popik et al., 2002), transcytosis (Alfsen and Bomsel, 2002), virion assembly 
and budding (Hollmann et al., 2013).  
The minimal region of gp41 that can bind GalCer is the MPR. This region, together 
with the adjacent transmembrane domain, is the most highly conserved element of the 
envelope protein (Alfsen et al., 2001; Alfsen and Bomsel, 2002; Miyauchi et al., 2005; 
Checkley et al., 2011). The MPR is the target of secretory IgAs that can be found in 
mucosal secretions of highly exposed, persistently seronegative individuals and may 
constitute one of very few potential correlates of protection against HIV-1 infection 
(Mayr et al., 1978; Devito et al., 2000; Devito et al., 2000; Miyazawa et al., 2009; Tudor 
et al., 2009; Trabattoni et al., 2012). These mucosal antibodies (Abs) were shown to 
possess anti-HIV responses including neutralization and blocking of transcytosis (Devito 
et al., 2000; Tudor et al., 2009). Significantly, epitopes within the MPER are recognized 
by three of only a handful of broadly neutralizing monoclonal Abs (mAbs) characterized 
thus far. Among them are 2F5 (Purtscher et al., 1994), 4E10 (Zwick et al., 2001) and 
more recently 10E8 (Huang et al., 2012). These mAbs also have other anti-HIV-1 
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activities including transcytosis-blocking (Shen et al., 2010) and Fc-mediated cytotoxicity 
(Tudor and Bomsel, 2011) and were shown to provide full protection against mucosal 
challenge when delivered intravenously (Baba et al., 2000; Mascola et al., 2000; Hessell 
et al., 2010). These attributes make the MPR a particularly interesting target for the 
development of a prophylactic vaccine against HIV-1 (Matoba et al., 2004; Matoba et al., 
2008; Matoba et al., 2009; Bomsel et al., 2011; Burton et al., 2012; Leroux-Roels et al., 
2013). 
Consequently, elucidation of the structure of the MPR is of interest and importance 
as it will instruct mucosal vaccine design against HIV-1. Liu et al. have reported that a 
portion of the MPER (Residues 662-683) forms a parallel three-stranded coiled coil 
stabilized by the addition of a C-terminal isoleucine zipper motif (Liu et al., 2009). 
However, it is difficult to determine whether MPER forms the three-stranded coiled coil 
by itself or if this MPER is forced into this conformation by its attachment to the three 
helix bundles with the isoleucine zipper, which forms a classic coiled coil (Harbury et al., 
1994). Instead of using an artificial motif to stabilize MPR, we want to study the structure 
of MPR together with its native transmembrane domain, which, similarly to the MPR, is 
highly conserved (Checkley et al., 2011). 
Studies on the function of the transmembrane domain of HIV-1 gp41 are limited. 
The transmembrane domain of HIV-1 gp41 plays an important role in anchoring the 
glycoprotein envelope complex into the viral membrane and is also crucial for its 
biological function in fusion and virus entry (Shang et al., 2008; Yue et al., 2009; Shang 
and Hunter, 2010; Montero et al., 2012). Mao et al. recently obtained a 6-Å structure of 
the membrane-bound HIV-1 envelope glycoprotein trimer in its uncleaved state by using 
	   16 
cryo-electron microscopy (EM), which included the transmembrane domain of gp41 
(Mao et al., 2013). Their low-resolution structural model proposed that the 
transmembrane domain of gp41 might form a left-handed three α-helical coiled coil, with 
a crossing angle of about 35°. This is the only structural information of the 
transmembrane domain of gp41 reported so far. The structure of MPR-TM at higher 
resolution is still needed for the structure-based design of a vaccine against HIV-1. 
There are two bottlenecks in membrane protein structure determination: high-yield 
membrane protein production and crystallization. There are two major reasons that 
account for the difficulty in producing large amounts of correctly-folded membrane 
proteins in bacteria. Most eukaryotic membrane proteins are inserted into the membrane 
in a process, which combines translation, targeting, folding and post-translational 
modifications. Despite some similarities and homologous elements, the membrane-
targeting pathways in bacteria are different enough to require engineering of eukaryotic 
genes to optimize their expression and accumulation. In addition, the limited membrane 
surface area in Escherichia coli may not only limit the total amount of properly-folded 
recombinant proteins made in this system, but also may have cytotoxic consequences by 
competitively reducing the production of vital host membrane proteins or by negatively 
affecting membrane physiology (Roosild et al., 2005). Mistic is a Bacillus subtilis 
integral membrane protein that autonomously folds into the membrane. It acts as a 
targeting signal and can be used for over-expression of other membrane proteins in their 
native conformations (Roosild et al., 2005). In our study, we developed an expression and 
purification strategy of MPR-TMTEV-6His fused to the C-terminus of Mistic. Surface 
plasmon resonance (SPR) measurements and ELISA experiments were carried out to test 
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if the epitope on the purified MPR-TMTEV-6His was exposed and could be recognized by 
the broadly neutralizing mAb 2F5 and 4E10. The purified MPR-TMTEV-6His was also 
biophysically characterized by size exclusion chromatography (SEC), MALDI-TOF MS, 
CD spectroscopy and dynamic light scattering (DLS). 
2.3 Materials and Methods 
2.3.1 Cloning, Bacterial Strains and Growth Conditions 
The MPR-TM649-705 construct is based on a deconstructed HIV-1 gp41 (dgp41) 
gene (GenBank Accession number JX534518) (Kessans et al., 2013), a chimera 
comprising the gp41 MPR derived from the B-clade MN isolate (GenBank accession 
number AF075722) and the transmembrane domain and cytoplasmic tail region of the C 
clade 1084i isolate (GenBank accession number AY805330). A more detailed description 
can be found in the Supporting information. Briefly, two tobacco etch virus (TEV) 
protease recognition sites were added to flank the coding sequence of MPR-TM649-705 and 
the construct was introduced into Gateway entry vector pCR8/GW/TOPO (Invitrogen). 
The construct was then fused to the B, subtilis Mistic protein by recombination into the 
Gateway destination vector pMistic (DNASU: pMIS2.1mv), which was a kind gift of Dr. 
Mark Vega, Salk Institute. For expression, the recombinant plasmid pMistic-MPR-TM649-
705
 was transformed into E. coli C41 (DE3). Cell culture growth conditions and 
recombinant protein induction are described in the Supporting information. 
2.3.2 Purification of MPR-TMTEV-6His 
The purification protocol is described in details in the Supporting information and 
will be only outlined here. Harvested cells were lysed with a microfluidizer 
(Microfluidics). Water-soluble proteins were separated from membrane proteins (and 
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other water-insoluble material) by centrifugation and discarded. The Mistic-MPR-TMTEV-
6His fusion protein was extracted by resuspending the pellet in ice-cold extraction buffer 
(PBS, 1% βDDM and protease inhibitor cocktail) and incubation with gentle shaking for 
3 h at 4 °C. Following centrifugation, the supernatant was collected and the protein was 
purified by TALON metal affinity chromatography (Clontech Laboratories, see 
Supporting information for details). The eluate was dialyzed (2000 Da cut-off dialysis 
tube, Sigma) overnight at 4 °C against 20 mM NaCl, 20 mM HEPES, pH 7.5. After 
dialysis, Tris-HCl pH 8.0, EDTA and DTT were added to the dialyzed protein (final 
concentrations: 50 mM, 0.5 mM and 1 mM, respectively). Protein preparation was 
proteolytically digested with TEV (Invitrogen, protease:substrate ratio of 20 U/182 µg, 2 
h at room temperature) resulting in >95% cleavage of Mistic-MPR-TMTEV-6His. 
The cleaved MPR-TMTEV-6His protein preparation was further purified by anion 
exchange chromatography using ÄKTApurifier 10 (GE Healthcare) and a Mono Q 5/50 
GL column (see Supporting information for details). Fractions containing cleaved MPR-
TMTEV-6His were pooled together for further biochemical and biophysical analysis. 
2.3.3 Size Exclusion Chromatography 
The purified MPR-TMTEV-6His preparations were characterized by SEC using 
ÄKTApurifier 10 (GE Healthcare) and a Superdex 200 10/300 GL column (24 mL bed 
volume, GE Healthcare). The CD spectroscopy-compatible mobile phase was 100 mM 
NaF, 20 mM NaH2PO4, pH 7.5, 0.02% βDDM as detailed in the Supporting information. 
2.3.4 Protein Determination, SDS-PAGE, Immunoblotting and ELISA 
Protein determination in crude and enriched preparations was carried out by the 
modified Lowry assay (Markwell et al., 1978). Protein concentration of pure preparations 
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of MPR-TMTEV-6His was determined by measuring A280 (ε = 32,290 cm-1M-1, obtained 
using Peptide Property Calculator at http://www.basic.northwestern.edu/ biotools/pro-
teincalc.html). 
Proteins were separated by SDS-PAGE (Schägger, 2006) and were subjected to 
silver staining (Lawrence et al., 2011) or to immunoblotting (see Supporting information 
for details) (Kessans et al., 2013). The authors thank the NIH AIDS Research and 
Reference Reagent Program (Divisions of AIDS, NIAID, NIH) for donation of the mAbs 
2F5 (catalog number 1475) and 4E10 (catalog number 10091). Chemiluminescence was 
detected using the BioSpectrum 500 C Imaging System (Ultra-Violet Products Ltd). 
ELISA was performed essentially as previously described (Matoba et al., 2008) and as 
detailed in the Supporting information. 
2.3.5 MALDI-TOF MS, CD Spectroscopy and DLS 
We used MALDI-TOF MS (Applied Biosystems) to accurately measure the 
molecular weight of the purified MPR-TMTEV-6His protein as detailed in the Supporting 
information.  
A JASCO J-710 CD spectropolarimeter was used for measuring the CD spectra of 
purified sample and the procedure, detailed in the Supporting information, was essentially 
according to Greenfield (Greenfield, 2006). Data analysis was performed using the 
CONTINLL program in CDPro software package by comparing the measured data with 
reference set option 10, which included 13 membrane proteins along with 43 soluble 
proteins (Sreerama and Woody, 2000). 
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DynaPro NanoStar M3300 from Wyatt Technology was used to carry out DLS 
measurements in the same buffer used for CD spectroscopy (see the Supporting 
information for details). 
2.3.6 Surface Plasmon Resonance (SPR) 
All experiments were performed on a KX5 Surface Plasmon Resonance Imaging 
(SPRi) System (Plexera). The KX5 SPRi procedure was previously described (Song et al., 
2013) and is detailed in the Supporting information. Preparation of custom SPRi chips is 
described in the Supporting information. We used gold chips coated with covalently 
linked Protein A/G that allowed immobilization of the test Abs through their Fc region, 
ensuring unimpeded interactions with antigens. To prevent nonspecific adsorption, the 
chip was blocked with BSA (5 mg/mL) before further analysis. The running buffer and 
dilution buffer of the analyte was 1xPBS containing 0.02% βDDM. In sequential runs, 
CTB (the negative control) at 850 nM, CTB-MPR at 600 nM and MPR-TMTEV-6His at 840 
nM were passed over the ligand surface at a flow rate of 1 µL/s, with a 300-s association 
and a 600-s dissociation. The chip was regenerated between runs with H3PO4 (1 : 200 of 
85% w/w) for 100 s followed by recoating with the desired antibody. Identical injections 
over blank protein A/G surfaces were subtracted from the data for kinetic analysis. SPRi 
data consisting of video images at 1-s resolution were analyzed with Data Analysis 
Module software from Plexera. The binding curve was analyzed and fitted with 1:1 
interaction model with Scrubber 2 software (Biologic Software). 
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2.4 Results and Discussion 
2.4.1 Cloning and Expression of MPR-TM649-705 
The membrane proximal region (MPR) of HIV-1 gp41 is important for the design 
of a mucosal vaccine against HIV-1. The transmembrane (TM) domain of HIV-1 gp41 
plays an essential role in anchoring the envelope complex into the viral membrane and is 
also crucial for its biological function in fusion and virus entry (Shang et al., 2008; Yue et 
al., 2009; Shang and Hunter, 2010). Bacterial expression of these two hydrophobic 
domains of HIV-1 has proved to be difficult and previous experiments in our laboratories 
making use of the P8CBD expression vector (Luo et al., 2009) resulted in extremely poor 
accumulation of properly-targeted MPR-TM (Gong, Kessans, Fromme and Mor, 
unpublished). In our study, the portion of the HIV-1 Env gene encoding for MPR-TM 
was cloned into the expression vector pMIS2.1mv to obtain pMistic-MPR-TMTEV-6His 
(Fig. 2.2A). This vector directs the tightly regulated expression of a C-terminal 
translation fusion between the B. subtilis integral membrane protein Mistic and MPR-
TMTEV-6His in E. coli (Fig. 2.2B, 2.2C). Mistic was previously shown to improve as a 
translational-fusion partner the expression and accumulation levels of several membrane 
proteins in their native conformations (Roosild et al., 2005). To allow the removal of the 
Mistic fusion partner prior to future crystallization experiments, two tobacco etch virus 
(TEV) protease recognition sites (Parks et al., 1994) were introduced by PCR primers. 
One TEV protease recognition site was introduced at the N-terminus of MPR-TM649-705 
and the other was located at the C-terminus (Fig. 2.2B, 2.2C). The recombinant plasmid 
pMistic-MPR-TMTEV-6His was transformed into E. coli C41 (DE3) cells for expression. 
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Figure 2.2 (A) Construction of the expression vector for pMistic-MPR-TMTEV-6His. See 
text and Supporting information for details. (B) Scheme of the Mistic-MPR-TMTEV-6His 
fusion protein. (C) Amino acid sequence of Mistic-MPR-TMTEV-6His. Purple: His-tag; 
Green: Mistic; red: MPR-TM; underlined ELDKWA: the mAb 2F5 core epitope; 
underlined NWFDI: the 4E10 mAb core epitope; blue: TEV recognition sites. Note that 
the cleavage occurred between Q and G residues of the TEV recognition sequence 
ENLYFQG. 
 
2.4.2 Purification of MPR-TMTEV-6His 
After cells were lysed by microfluidization, the majority of the fusion protein 
Mistic-MPR-TMTEV-6His was found in the membrane fraction, and a purification protocol 
was developed to allow efficient purification without compromising the structural 
integrity of the protein (Fig. 2.3). Following extensive screening of various detergents 
(data not shown), βDDM at 1% was used to extract the fusion protein from the 
membrane. The βDDM extract was subjected to TALON metal affinity chromatography 
to separate His-tagged Mistic-MPR-TMTEV-6His from other proteins (Porath et al., 1975; 
Hochuli et al., 1987). The second elution fraction contained the majority of His-tagged 
	   23 
proteins, which showed a complex pattern of banding upon SDS-PAGE fractionation 
(Fig. 2.4). The very top band (marked with blue arrows) corresponded to the fusion 
protein Mistic-MPR-TMTEV-6His, with a molecular mass of 31 kDa, in good concordance 
with its calculated expected size. Four contaminant bands were visible. The second band 
from the top on the silver-stained SDS-PAGE in Figure 4 corresponded to a His-tagged 
fragment of Mistic and MPR-TMTEV-6His as it could be detected in immunoblots by the 
MPER-specific mAb 2F5 (Fig. 2.4). In contrast, the three lower bands, clearly visible on 
the silver-stained gels, did not react with the 2F5 Ab (Fig. 2.4) and could be His-tagged 
fragments of Mistic without MPR or unrelated E. coli proteins. We observed that 
degradation was a common problem for Mistic fusion constructs (data not shown).  
 
Figure 2.3. MPR-TMTEV-6His purification scheme. 
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Figure 2.4. Purification of Mistic-MPR-TMTEV-6His by metal affinity chromatography and 
its cleavage by TEV protease. Fractions were resolved by SDS-PAGE and visualized by 
silver staining (left) or immunoblotting with the mAb 2F5 (right). Blue arrows: Mistic- 
MPR-TMTEV-6His. Red arrows: cleaved MPR-TMTEV-6His. 
 
The next step in our purification scheme (Fig. 2.3) was the specific cleavage of the 
fusion protein followed by anion exchange chromatography to separate the MPR-TMTEV-
6His protein from its Mistic fusion partner. The TALON column eluates were dialyzed to 
remove the imidazole and the ionic conditions of the buffer were adjusted to ensure 
efficient cleavage by the TEV protease. We expected the fully-processed MPR-TM 
protein to have a molecular weight of 7.8 kDa, if both the N-terminal and C-terminal 
TEV recognition sites were to be cleaved. However, extensive digestion by TEV yielded 
a protein band (indicated by red arrows in Fig. 2.4) with apparent molecular mass greater 
than 10 kDa that cross-reacted with the MPR-specific mAb 2F5. Moreover, subjecting 
the cleavage products to a second TALON purification step, demonstrated that this >10 
kDa cleavage protein retained a functional His-tag that allowed its efficient binding to the 
column and required high concentration of imidazole (250 mM) for elution (data not 
shown). Our results are therefore compatible with the lack of TEV cleavage at its C-
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terminal site of the protein. The final product therefore consists of the MPR-TM with its 
C-terminal His-tag still attached (called hereafter “MPR-TMTEV-6His”). The expected 
molecular mass of this polypeptide was 11.9 kDa. Lack of cleavage at the C-terminal 
TEV recognition site could be explained by its proximity to TM domain, which is likely 
to be fully embedded in the detergent micelle, thereby the hydrophilic sugar heads of the 
βDDM molecules may obscure the TEV cleavage site or may otherwise impede the 
enzyme’s proteolytic activity. 
Retention of the C-terminal His-tags on the MPR-TMTEV-6His protein interfered with 
our original plan to separate it from the other cleavage products containing the Mistic 
protein by the second TALON metal-affinity chromatography step. Instead, we turned to 
size-exclusion chromatography (SEC) and experimented with two types of SEC columns, 
Superdex 75 10/300 GL and Superdex 200 10/300 GL, to separate MPR-TMTEV-6His from 
8HisMistic6His and other degradation products, but MPR-TMTEV-6His could not be purified 
by either of the two columns (data not shown).  
Finally, Mono Q anion exchange chromatography was used to further purify the 
MPR-TMTEV-6His protein. The optimal conditions for Mono Q ion exchange 
chromatography were chosen based on several prior small-scale tests. MPR-TMTEV-6His 
eluted as the main elution peak (A9 in Fig. 2.5A) while 8HisMistic6His and other 
degradation proteins were in the flowthrough (A1 in Fig. 2.5A) and a shoulder peak (A 
10 and A11 in Fig. 2.5A) of the main elution peak. The protein elution was monitored at 
280 nm and the fractions were analyzed by SDS-PAGE (Fig. 2.5B). The band labeled by 
red arrowheads corresponds to MPR-TMTEV-6His while the band pointed out by green 
arrowheads corresponds to the cleaved 8HisMistic6His. Fraction A9 was overloaded so it 
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was very difficult to determine if the strong band was MPR-TMTEV-6His only or the 
mixture of 8HisMistic6His and MPR-TMTEV-6His. Fraction A9 was diluted 10 times and 
reanalyzed by SDS-PAGE (Fig. 2.5C). The result shown in Fig. 2.5C confirms that 
fraction A9 only contains MPR-TMTEV-6His. The protein preparations corresponding to 
fraction A9 were used for future analysis. 
 
Figure 2.5. Separation of Mistic-MPR-TMTEV-6His cleavage products by Mono Q anion 
exchange chromatography. (A) Chromatogram. (B) Fractions were resolved by SDS-
PAGE and visualized by silver staining. Red arrowheads: MPR-TMTEV-6His; green 
arrowheads: 8HisMistic6His. (C) SDS-PAGE analysis of 10-fold diluted fraction A9 (dA9). 
L: ladder. 
 
The presence of the uncleaved C-terminal tail containing the C-terminal TEV 
recognition site, an attR2 site and a 6His-tag (Fig. 2.2C) may raise the concern that it 
might affect future crystallization of MPR-TMTEV-6His. However, this seems unlikely as 
the protein data bank (PDB) contains several examples of high-resolution structures 
	   27 
containing such an artificial protein domain including a 1.55 Å crystal structure of the 
thioredoxin domain of human thioredoxin-like protein 2 (PDB: 2WZ9). 
2.4.3 Purified MPR-TMTEV-6His is Folded and Stable 
Circular dichroism (CD) spectroscopy was used to estimate the secondary structural 
content of MPR-TMTEV-6His. The CD spectra of MPR-TMTEV-6His displayed one positive 
band at 195 nm and two negative bands at 208 nm and 222 nm (Fig. 2.6), which is 
characteristic of α-helical proteins (Greenfield, 2006). Data analysis with CONTINLL in 
the CDPro software package (Sreerama and Woody, 2000) produced an estimation of 
52.2% α helices, 6.3% β sheets, 14.9% turns and 26.5% random coils and the root-mean-
square deviation (RMSD) value was 0.055. Estimation with CONTINLL was similar to 
the secondary structure prediction with server APSSP2 (Raghava, 2002), which predicted 
59.6% α helices. The 2-Å crystal structure of the gp41528-683 indicated that the MPR 
(Residues 649 to 683) might form an α-helix (Buzon et al., 2010). As reported by Mao et 
al. (Mao et al., 2013), The 6-Å cryo-EM structure of the uncleaved HIV-1 envelope 
glycoprotein trimer suggests that the transmembrane domain (Residues 684- 705) of gp41 
might be an α-helix as is generally assumed (but see Steckbeck and co-workers for a 
different view (Steckbeck et al., 2013)). Please note that the Env structure proposed by 
Mao et al. (Mao et al., 2013) differs from other recent structures based on 
crystallographic and EM studies, and some aspects of that model remain controversial  
(Buzon et al., 2010; Shi et al., 2010; Lyumkis et al., 2013). In particular, the organization 
of secondary structure elements in the gp41 ectodomain of the structure proposed by Mao 
et al. (Mao et al., 2013) is dramatically different from that of the six α-helix bundles seen 
in the post-fusion form. Specifically, according to Mao et al. (Mao et al., 2013), the NHR 
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and CHR domains are broken into eight short α-helices in striking opposition to six 
helical bundle. In any event, the CD spectra indicate that MPR-TMTEV-6His is folded after 
purification. 
 
Figure 2.6. CD spectrometry demonstrated that purified MPR-TMTEV-6His was α-helical. 
With one positive band at 195 nm and two negative bands at 208 nm and 222 nm, the CD 
spectra of the protein were typical for α-helical proteins 
 
We used dynamic light scattering (DLS) to further demonstrate that purified E. 
coli-derived MPR-TMTEV-6His is stably folded and monodisperse as these are critical 
factors affecting crystallization (Ferré-D'Amaré and Burley, 1997). DLS is a technique 
that is very sensitive for the detection of aggregates. Our DLS analysis demonstrated that 
purified MPR-TMTEV-6His was monodisperse, with polydispersity of the protein-detergent 
complex estimated to be only 12.3% (Fig. 2.7 and Supporting Table 2.1). Moreover, we 
have used DLS to monitor the stability of purified MPR-TMTEV-6His protein at 4 °C over 
time. Our result shows that MPR-TMTEV-6His remains monodisperse for at least 10 days at 
4 °C (Fig. 2.7 insert, Supporting Fig. 2.1, page 48). The DLS results indicate that MPR-
TMTEV-6His is a monodisperse and stable candidate for crystallization. 
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Figure 2.7. DLS demonstrated that purified MPR-TMTEV-6His was highly monodisperse. 
Sample contained MPR-TMTEV-6His (0.22 mg/mL) in 100 mM NaF, 20 mM NaH2PO4, pH 
7.5, 0.02% βDDM. Insert: the purified MPR-TMTEV-6His was stored at 4 °C and measured 
by DLS at day 1, 2, 3, 4, 7 and 10 respectively. The polydispersity remained below 25% 
(please refer to Supporting Table 2.2 and Supporting Figure 2.1 for details), which 
indicated that purified MPR-TMTEV-6His was monodisperse for at least 10 days at 4 °C. 
 
2.4.4 Molecular Mass of MPR-TMTEV-6His and Its Oligomeric State 
We used MALDI-TOF MS to determine the accurate molecular mass of 
MPR-TMTEV-6His and the resulting spectrum revealed a protein peak of 11,874 ± 4 Da 
(Fig. 2.8). This agreed very well with the theoretical molecular weight of MPR-TMTEV-
6His, which was predicted to be 11,872 Da based on the sequence (Fig. 2.2) and the SDS-
PAGE analysis (Fig. 2.4). The shoulder peak at 12,138 Da could be assigned to the 
complex of MPR-TMTEV-6His and the matrix sinapinic acid whose molecular weight was 
224 Da.  
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Figure 2.8. MALDI-TOF spectra of MPR-TMTEV-6His were in perfect agreement with the 
calculated molecular mass of the protein at 11,872 Da. 
 
The MS results confirm the predicted molecular mass of the MPR-TMTEV-6His. 
Proteins are denatured by MALDI using sinapinic acid and do not provide information 
about the oligomeric information. It was, therefore, of interest to check the 
oligomerization state of the purified protein. Our DLS results showed that the Stokes 
radius of the detergent-protein complex was 4.68 nm, which corresponded to a molecular 
mass of 124 kDa (Supporting Table 2.1). This indicates that MPR-TMTEV-6His 
polypeptides form a larger complex consisting of several monomeric subunits. However, 
the oligomeric state of the complex is difficult to determine, as it exists in the form of 
protein-detergent complex. 
We have used analytical SEC to verify the quaternary structure of purified MPR-
TMTEV-6His and to provide additional estimate as to its molecular mass and its oligomeric 
state in its detergent-solubilized state (Fig. 2.9). The SEC chromatogram revealed a single 
symmetric peak that eluted at 13.70 mL (Fig. 2.9A). The molecular weight of this peak 
was ~123 kDa, calculated based on the standard curve (Fig. 2.9B). This size corresponds 
to the MPR-TMTEV-6His oligomer embedded into a βDDM micelle and was very similar to 
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the molecular weight estimation obtained by DLS (124 kDa, Supporting Table 2.1 and 
Fig. 2.7). 
 
Figure 2.9. Estimation of the molecular mass of purified native MPR-TMTEV-6His. (A) 
SEC of MPR-TMTEV-6His revealed a single symmetric peak eluted at 13.7 mL 
corresponding to ~123 kDa based on the standard curve. (B) The standard curve of 
Superdex 200 10/300 GL column using the following standard proteins: aprotinin (6.5 
kDa), RNase A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (43 kDa), 
conalbumin (75 kDa), aldolase (158 kDa) and ferritin (440 kDa). Kav is the partition 
coefficient, which can be calculated as following: (elution volume – void volume) / (total 
volume – void volume). 
 
The excellent correspondence of the DLS and SEC data supported our aim to use 
the information to assess the oligomeric structure of MPR-TMTEV-6His. The average 
molecular weight of “empty” βDDM micelles measured by DLS was 68 kDa (data not 
shown). However, detergent shell in the protein-detergent complex is often larger than 
the empty micelle because the detergent must cover all the hydrophobic surface of the 
protein. Therefore, the estimation of the oligomeric state of the protein inside the micelle 
is complicated. It is likely that the presence of embedded proteins should change the 
expected size of the micelle. Other estimates published in the past indicated that detergent 
to protein ratio values rang 2.4-3.5 (g/g) (Butler et al., 2004; Bamber et al., 2006). A 
trimer embedded in βDDM micelles could therefore show an apparent molecular mass in 
the range of 121-160 kDa. In either case, the values for a dimer (81 – 107 kDa) would be 
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lower than the observed value. While the definitive subunit composition of the MPR-
TMTEV-6His is hard to resolve at this stage, it is clear that the protein is oligomeric, an 
important structure-function attribute of the native gp41 molecule. 
2.4.5 Purified MPR-TMTEV-6His is Recognized by the Broadly Neutralizing mAbs 2F5 
and 4E10 
An important structure-function attribute of gp41 is its ability to bind to broadly 
neutralizing mAbs. It was therefore of great importance to test if the deconstructed 
version of the transmembrane subunit of the envelope protein could be recognized by the 
broadly neutralizing mAbs 2F5 and 4E10. The 2F5 and 4E10 mAbs interacts with a 
highly conserved sequence of MPER. This part is "hidden" inside a tight helix bundle in 
most of the structural models reported from MPER (Liu et al., 2009; Buzon et al., 2010). 
Only one structure has been solved containing a shortened NHR (HR1) region, which left 
MPER accessible to 2F5 Abs (Shi et al., 2010). We used ELISA to determine if the 2F5 
antibody was able to bind to purified MPR-TMTEV-6His in its non-denatured state (Fig. 
2.10). The results (Fig. 2.10A, rows C and D) clearly indicate that the MPR-TMTEV-6His 
protein is indeed recognized by the 2F5 Abs. As expected, a positive control consisting of 
a fusion protein of a fusion protein of the cholera toxin subunit B with MPR also react 
with the 2F5 Abs (CTB-MPR, Fig. 2.10A, rows E and F). CTB-MPR has previously been 
shown to react with 2F5 Abs (Matoba et al., 2004) and was able to elicit Abs that could 
block the transcytosis progression of HIV through the tight epithelia models (Matoba et 
al., 2004). In CTB-MPR, the pentameric nature of CTB is thought to hinder MPR from 
assuming the trimeric post-fusion conformation that does not allow for antibody access to 
the 2F5-binding site (Lee et al., 2014).  
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To affirm the ELISA results and to quantitatively assess the affinity of MPR-
TMTEV-6His to the two broadly neutralizing Abs 2F5 and 4E10, we employed surface 
plasmon resonance (SPR) measurements (Fig. 2.10B, C and Table 2.1). The results 
demonstrate very high affinity (nanomolar and subnanomolar range) of the MPR in the 
context of its transmembrane domain (MPR-TMTEV-6His, Fig. 2.10B) and as a fusion 
protein with CTB (Fig. 2.10C), in good agreement to our previously published results 
concerning CTB-MPR (Matoba et al., 2008). The calculated dissociation constant (KD) of 
2F5 from MPR-TMTEV-6His and CTB-MPR was 2.2 ± 0.2 nM and 0.8 ± 0.2 nM, 
respectively. The calculated dissociation constant (KD) of 4E10 from MPR-TMTEV-6His 
and CTB-MPR was 2.1 ± 0.0 nM and 0.5 ± 0.2 nM, respectively. As a negative control, 
we tested CTB by itself, which showed no appreciable binding to either 2F5 or 4E10 
(data not shown).  
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Figure 2.10. Purified native MPR-TMTEV-6His can bind to 2F5 and 4E10 mAbs. (A) Image 
of the developed ELISA plate. Row A: control uncoated wells. Rows B-D: wells coated 
with serially diluted MPR-TMTEV-6His. Rows E, F and H: wells coated with serially 
diluted CTB-MPR. Row G: wells coated with serially diluted CTB. All rows except B 
and H were overlaid with the mAb 2F5. (B, C) SPR analysis. Association/dissociation 
traces of MPR-TMTEV-6His (B) and CTB-MPR (C) with either 2F5 or 4E10 mAbs. Traces 
are average of four independent measurements and the dissociation constants (KD) are 
listed in the inserts (mean ± SD).  
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Immobilized ligand Flowing analyte ka, ms-1 kd, s-1 KD, M 
2F5 MPR-TM 4.7±0.3E4 9.9±0.1E-5 2.2±0.2E-9 
4E10 MPR-TM 2.3±0.1E4 5.0±0.4E-5 2.1±0.0E-9 
2F5 CTB-MPR 5.5±0.7E4 4.2±1.0E-5 0.8±0.2E-9 
4E10 CTB-MPR 4.7±0.3E4 2.5±1.3E-5 0.5±0.2E-9 
Table 2.1. Association and dissociation rate constants derived from SPR analysis. 
 
The ELISA and SPR results indicated that the 2F5 and 4E10 epitopes in MPR-
TMTEV-6His was exposed and accessible for strong 2F5 (and 4E10) binding. These results 
are in excellent agreement with experiments of other groups aimed at recreating an early 
fusion intermediate in which the epitopes of 2F5 and 4E10 are exposed to allow 
interactions with the two neutralizing monoclonal mAbs (Qiao et al., 2005; Kim et al., 
2007; Frey et al., 2008; Wang et al., 2011; Lutje Hulsik et al., 2013). For example, Frey 
et al. (Frey et al., 2008) created a prehairpin intermediate consisting of a trimerization tag 
fused to the MPER, and to the NHR sandwiched between a duplicated CHR. The NHR 
was apparently prevented from masking the MPER, thus allowing its interactions with 
2F5. More recently, Lutje-Hulsik et al. (Lutje Hulsik et al., 2013) have used an even 
simpler construct that contained the TM domain of gp41, the MPER and the CHR to 
demonstrate similar high affinities to several neutralizing monoclonal Abs. Our construct 
contains no artificial trimerizing fusion partners, and contains only the C-terminal half of 
the CHR.  
In contrast, both Frey et al. and Lutje-Hulsik et al. (Frey et al., 2008; Lutje Hulsik 
et al., 2013), as well as others, demonstrated that gp41 in its prefusion conformation 
(present on the virions, for example see (Cavacini et al., 2002)) cannot interact with 2F5 
or 4E10 prior to Env’s interactions with the CD4 receptor (Cavacini et al., 2002; Leaman 
et al., 2010). Similarly, a post-fusion conformation precludes 2F5 and 4E10 binding (Frey 
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et al., 2008; Lutje Hulsik et al., 2013). For example, Liu et al. (Liu et al., 2009) reported 
tight helix bundle structure for MPER. In their study, MPER of gp41 was fused to a 
trimeric C-terminal isoleucine zipper motif and formed a parallel three-stranded coiled 
coil. The 2F5 epitopes were buried within the interface between the MPER helices and 
could not be recognized by 2F5 (Liu et al., 2009). Our results provide further 
experimental evidence of the importance of the transmembrane domain of gp41 to 
preserve the immunological signature of the membrane proximal region of gp41 
(Montero et al., 2012), probably mimicking in a pre-hairpin intermediate. It also 
demonstrates the need to remove the heptad repeat regions.  
2.5 Conclusion 
In summary, we describe here the design, expression and purification of a protein 
construct that includes MPR and the transmembrane domain of gp41 (MPR-TMTEV-6His), 
which reacts with the broadly neutralizing Abs 2F5 and 4E10 and thereby may represent 
an immunologically relevant conformation mimicking a pre-hairpin intermediate of gp41. 
The quantity and quality of purified MPR-TMTEV-6His reported here make the protein 
suitable for crystallization experiments and NMR studies as a prerequisite for structural 
studies, which may guide the structure-based design of vaccines against HIV-1 in the 
future. 
2.6 Supporting Information 
2.6.1 Supporting Material and Methods  
2.6.1.1 Cloning, Bacterial Strains and Growth Conditions 
The MPR-TM649-705 construct is based on a deconstructed HIV-1 gp41 (dgp41) 
gene (GenBank Accession number JX534518) (Kessans et al., 2013), a chimera 
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comprising the gp41 MPR derived from the B-clade MN isolate (GenBank accession 
number AF075722) and the transmembrane domain and cytoplasmic tail region of the C 
clade 1084i isolate (GenBank accession number AY805330). The coding sequence of 
MPR-TM649-705 was amplified by PCR from pTM601 (Kessans et al., 2013) using the 
forward primer (5’ GAGAATCTTTATTTTCCAGGGCATGGGATCTCAAACTCAAC 
3’) and the reverse primer (5’ GCCCTGAAAATAAAGATTCTCTTACACCATAGAC 
AACACAG 3’) and then ligated into the pCR8/GW/TOPO vector (pCR8/GW/TOPO TA 
Cloning Kit, Invitrogen) to yield a Gateway entry clone. The entry clone was screened by 
restriction analysis and sequencing to confirm the presence and correct orientation of 
MPR-TM649-705. Two recognition sites for the tobacco etch virus (TEV) protease were 
introduced by PCR primers. One was on the N-terminus of MPR-TM649-705 and the other 
was on the C-terminus. MPR-TM649-705 was further cloned into a Gateway destination 
vector pMistic (Vector name: pMIS2.1mv, DNASU) from the entry clone 
pCR8/GW/TOPO using a LR recombinant reaction (Gateway LR Clonase II Enzyme 
Mix, Invitrogen) to generate the expression clone pMistic-MPR-TM649-705. The 
expression vector pMistic (Vector name: pMIS2.1mv, DNASU) was a kind gift of Dr. 
Mark Vega (Center for Structures of Membrane Proteins, PSI, Salk Institute) to the 
Center for Membrane Protein in Infectious Diseases (MPID) of Arizona State University. 
The recombinant plasmid pMistic-MPR-TM649-705 was transformed into E. coli C41 
(DE3) (Lucigen) for expression. Recombinant E. coli C41 (DE3) cells were grown in 
Terrific Broth medium containing 50 µg/mL of ampicillin in a shaker at 37 °C and 200 
rpm. Recombinant expression of our protein in E. coli C41 (DE3) cells was induced by 
adding Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 200 µM 
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when the OD600 reached 0.6-0.8. The cells were then incubated for another 24 hours at 25 
°C and 200 rpm. The OD600 after 24-hours induction was 2.0. The cells were harvested by 
centrifugation at 5000 xg for 15 min at 4 °C. Cell pellets were stored at -80 °C for future 
use.  
2.6.1.2 Purification of MPR-TM 
Cells stored at -80 °C were thawed and resuspended in ice-cold phosphate buffered 
saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) 
with Sigma EDTA-free protease inhibitor cocktail tablet. Cell pellets (15 g) were 
resuspended in 100 mL of PBS containing one Sigma EDTA-free protease inhibitor 
cocktail tablet. Cells were then lysed by passing through a microfluidizer (Microfluidics) 
twice at 90 psi. The cell lysate was centrifuged at 20,000 xg for 20 min at 4 °C. The 
supernatant was discarded and the pellet, containing the membrane fraction, 
peptidoglycan cell wall and other aqueous-insoluble material was stored at -80 °C 
overnight. We found that freezing and thawing the sample makes resuspension easier, 
probably because high molecular weight DNA in the sample becomes sheared in the 
process. If processed without the freeze-thaw treatment, the detergent extract is highly 
viscous and too sticky to pass through the metal affinity column in the next step. 
To extract the MPR-TM from the membrane, the membrane pellet (obtained from 
15 g of cells) was thawed and resuspended in 100 mL of ice-cold PBS with 1% n-β-
dodecyl-D-maltoside (βDDM) and a Sigma EDTA-free protease inhibitor cocktail tablet. 
The βDDM-containing suspension was incubated with gentle shaking for 3 h at 4 °C and 
then centrifuged down at 20,000 xg for 20 min at 4 °C. The supernatant was collected and 
the protein was purified by TALON metal affinity chromatography (Clontech 
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Laboratories) using a hybrid batch/gravity-flow procedure. In this hybrid procedure, the 
binding step was performed in a batch format in a column (Bio-Rad Econo-Column, 5 cm 
× 20 cm, maximum volume: 393 mL) that accommodated ~20 times the resin bed volume 
(typically 20 mL) for homogeneous binding. The washing and elution steps were then 
performed by gravity-flow. Prior to use, the column was washed with 3 column volumes 
(CVs) of H2O and equilibrated with 3 CVs of binding buffer (20 mM bicine pH 8.0, 500 
mM NaCl, 0.05% βDDM). The βDDM extract was loaded onto the column and incubated 
with TALON resin while gently shaking for 1 hour at 4 °C. The resin was let to settle in 
the column and the flowthrough was collected for SDS-PAGE analysis. The resin was 
washed with 6 CVs of binding buffer followed by 12 CVs of wash buffer (20 mM bicine, 
500 mM NaCl, pH 8.0, 10 mM imidazole, 0.05% βDDM). The 10th and 12th washes 
were collected for SDS-PAGE analysis. After the washing steps, elution buffer (20 mM 
bicine, 500 mM NaCl, pH 8.0, 250 mM imidazole, 0.05% βDDM, total volume 2.5 CVs) 
was applied onto the column to elute His-tagged proteins. The eluate was collected in 10 
mL (first) or 20 mL (all subsequent) fractions.  Eluate samples were kept for SDS-PAGE 
analysis.  
The eluted proteins were dialyzed against 20 mM NaCl, 20 mM HEPES, pH 7.5 
using a 2000 Da cut-off dialysis tube (Sigma) overnight at 4 °C. After dialysis, Tris-HCl 
pH 8.0, EDTA and dithiothreitol (DTT) were added to the dialyzed protein to final 
concentrations of 50 mM, 0.5 mM and 1 mM, respectively. TEV protease (Invitrogen) 
was then added to a final protease:substrate ratio of 20 U/ 182 µg, and the reaction 
mixture was incubated for 2 h at room temperature. Under these conditions >95% of the 
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protein was cleaved. The protein concentration was determined by modified Lowry assay 
(Markwell et al., 1978).  
The cleaved MPR-TM protein sample was further purified by Mono Q anion 
exchange chromatography using an ÄKTApurifier 10 (GE Healthcare) and a Mono Q 
5/50 GL column (1 mL bed volume, GE Healthcare). Optimal conditions for Mono Q 
anion exchange chromatography purification of MPR-TM were chosen based on the 
results of extensive small scale tests. All buffers used for FPLC were filtered through a 
0.2 µm membrane (Millipore) and degassed. After the column was equilibrated with 10 
ml of buffer A (20 mM HEPES, pH 7.5, 0.02% βDDM), the dialyzed MPR-TM sample 
was injected onto the column. The column was then washed with 30 ml of buffer A at 2 
mL/min, followed by an increasing linear gradient of buffer B (20 mM HEPES, pH 7.5, 1 
M NaCl, 0.02% βDDM) from 0% to 25% at 2 ml/min in 20 min, leading to the elution of 
cleaved MPR-TM. After elution, the column was washed with 100% buffer B to wash the 
column at the end of the run. Protein elution was monitored by absorbance at 280 nm and 
the fractions were analyzed by 14% SDS-PAGE and immunoblot analysis. Fractions 
containing cleaved MPR-TM were pooled together for further biophysical analysis. 
2.6.1.3 SDS-PAGE and Western Blot Detection 
Proteins were separated by SDS-PAGE carried out as described by Schägger on 
14% polyacrylamide gels(Schägger, 2006) and either stained by the silver staining 
method(Lawrence et al., 2011) or subjected to immunoblotting. Proteins in gels were 
transferred onto a PVDF membrane (Bio-Rad) in the presence of transfer buffer (192 mM 
glycine, 24.9 mM Tris base, 20% v/v methanol) using a Bio-Rad Mini Trans-Blot 
Module at 220 mA for 60 min. The PVDF membrane was incubated with 5% PBST-M 
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(PBS supplemented with 0.05% Tween 20 and 5% non-fat milk) for 60 min at room 
temperature. The HIV-1 gp41 mAb 2F5 (cat# 1475), obtained from Hermann Katinger 
through the NIH AIDS Research and Reference Reagent Program, Divisions of AIDS, 
NIAID, NIH, was used as the primary detecting Ab. Following another 60-min 
incubation with the primary Ab (1:10000 dilution), the membrane was rapidly washed 
three times with PBST (PBS supplemented with 0.05% Tween 20) and followed by a 30-
min incubation with PBST. The membrane was then incubated for 60 min with a rabbit 
anti-human IgG-HRP conjugate (Santa Cruz Biotechnology) as the secondary antibody 
and StrepTactin-HRP conjugate (Bio-Rad, to detect the MW standards) that were diluted, 
respectively, 1:20,000 or 1: 5,000 in 5% PBST-M. The membrane was washed in PBST 
as described above. Following the fourth PBST wash, the wet membrane was developed 
using Immun-Star HRP substrate kit (Bio-Rad) per manufacturer’s instructions. 
Chemiluminescence was detected using the BioSpectrum 500 C Imaging System (Ultra-
Violet Products Ltd). 
2.6.1.4 Size Exclusion Chromatography 
The purified MPR-TM from Mono Q anion exchange chromatography was 
characterized by size exclusion chromatography (SEC) using an ÄKTApurifier 10 (GE 
Healthcare) and a Superdex 200 10/300 GL column (24 ml bed volume, GE Healthcare). 
The mobile phase was 100 mM NaF, 20 mM NaH2PO4, pH 7.5, 0.02% βDDM. This 
buffer was used because it has little absorption in the UV for the subsequent circular 
dichroism (CD) measurements. The column was calibrated using the Gel Filtration LMW 
Calibration Kit and Gel Filtration HMW Calibration Kit from GE Healthcare. The kit 
contained blue dextran 2000 (2000 kDa) and eight standard proteins: aprotinin (6.5 kDa), 
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RNase A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 
kDa), aldolase (158 kDa), ferritin (440 kDa) and thyroglobulin (669 kDa). Blue dextran 
2000 was used to determine the void volume of the column. Seven standard proteins 
except thyroglobulin (669 kDa) were used to obtain the standard curve for molecular 
mass estimation.  
2.6.1.5 Mass Spectrometry 
We used matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) 
Mass spectrometry (MS) to accurately measure the molecular weight of the purified 
MPR-TM protein. Purified MPR-TM (1 µL of 1 mg/mL) was added to 4 µl of sinapinic 
acid matrix, which was prepared daily as a saturated solution in 50% acetonitrile/H2O and 
0.1% trifluoroacetic acid (TFA). The protein/ matrix mixture (1 µL) was added onto a 
steel target plate (Applied Biosystems) and allowed to dry in air.  The plate was then 
placed into Applied Biosystems DE-STR MALDI-TOF mass spectrometer, and spectra 
were collected in a positive linear mode over a mass range from 3 to 30 kDa. Final results 
represented the average of 10 separate spectra with each spectrum in turn the average of 
100 laser shots.  
2.6.1.6 ELISA 
ELISA plates (96-wells, Becton Dickinson) were coated by the test proteins, 5-fold 
serially diluted (starting concentration of 200 µg/mL) in coating buffer (15 mM Na2CO3, 
35 mM NaHCO3, 3 mM NaN3, pH 9.6) at 37 °C for 1 h. Test proteins included purified 
MPR-TM (this work), CTB-MPR (Lee et al, in preparation and reference (Matoba et al., 
2008)), a fusion protein between the MPR and the B subunit of cholera toxin (CTB), and 
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CTB serving as a negative control (List Biological Laboratories). Blank (uncoated) wells 
and omission of the primary Ab served as additional negative controls.  
After protein coating, the wells were washed two times with PBST buffer, followed 
by incubation with 5% PBST-M buffer at room temperature for 1 h. Subsequently, the 
wells were rinsed two times with deionized H2O. The plates were then incubated at 37 °C 
for 1 h with 1% PBST-M (PBS supplemented with 0.05% Tween 20 and 1% non-fat 
milk) with the mAb 2F5 added (50 ng) to the indicated wells. Subsequently, all wells 
were washed three times with PBST buffer, followed by incubation with goat anti-human 
IgG (Sigma) at 1:1000 dilution in 1% PBST-M at 37 °C for 1 h. The wells were then 
washed three times with deionized H2O and developed with Sigma FAST OPD (o-
phenylenediamine dihydrochloride) substrate (Sigma). The plates were imaged and the 
absorbance at 490 nm was measured using a microplate reader (Spectra Max 340PC, 
Molecular Devices). Absorbance data plotted against protein concentrations were fitted 
by nonlinear regression using GraphPad Prism 4.0 to obtain approximate dissociation 
constant (Kd) values of antigen-Ab interactions. 
2.6.1.7 Circular Dichroism (CD) Spectroscopy and Dynamic Light Scattering (DLS) 
A JASCO J-710 CD spectropolarimeter was used for measuring the CD spectra of 
purified sample. The SEC-purified MPR-TM (eluted in 100 mM NaF, 20 mM NaH2PO4, 
pH 7.5, 0.02% βDDM) was concentrated to 0.22 mg/ml by a 50-kDa concentrator 
(polyethersulfone membrane, Sartorius) and used for CD measurement. Buffer-only 
samples were measured as blank and the blank values were subtracted from the CD 
measurement of MPR-TM. CD spectra were recorded from 185 to 260 nm at 25 °C using 
a 0.1 cm quartz cuvette. Parameters were set at 1 nm data pitch, continuous scanning 
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mode, a scanning speed of 50 nm/min, a response of 4 s, and a spectral bandwidth of 1 
nm. Output spectra were generated based on an accumulation of five scans. The molar 
ellipticity in deg.·cm2/dmol was calculated as described by Greenfield’s et al. 
(Greenfield, 2006). Data analysis was performed using the CONTINLL program in 
CDPro software package by comparing the measured data with reference set option 10, 
which included 13 membrane proteins along with 43 soluble proteins(Sreerama and 
Woody, 2000). The secondary structure content of purified MPR-TM was estimated 
based on the CONTINLL analysis.  
DynaPro NanoStar M3300 from Wyatt Technology was used to carry out DLS 
measurements in the same buffer used for CD spectroscopy. In addition, DLS 
measurements were conducted with solutions containing 1%, 0.1% and 0.02% βDDM in 
100 mM NaF, 20 mM NaH2PO4, pH 7.5 to estimate the molecular mass of βDDM 
micelles. A 120 mW laser of 660 nm was used as the light source.  For each 
measurement, the number of acquisitions was 10 and each acquisition time was 20 s. All 
measurements were carried out at 20 °C. 
2.6.1.8 Determination of the Protein Concentration 
Protein determination was carried out by the modified Lowry assay(Markwell et al., 
1978). Protein concentration of pure preparations of MPR-TM was determined by 
measuring A280 (ε= 32,290 cm-1M-1, obtained using Peptide Property Calculator at 
http://www.basic.northwestern.edu/biotools/proteincalc.html). 
2.6.1.9 Surface Plasmon Resonance (SPR) 
All experiments were performed on a KX5 Surface Plasmon Resonance Imaging 
(SPRi) System (Plexera). The Kx5 SPRi procedure were previously described (Song et 
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al., 2013). The SPRi chip  was a 25 mm x 75 mm BK7 optical glass slide coated with a 
50 nm-thick gold layer and a 1.5 nm-thick chromium adhesive layer (Plexera). The gold 
slide was cleaned with oxygen plasma for 2 min at 29.6 W, and was immediately 
incubated for 16 h at 4 ºC with 20-(11-mercaptoundecanoyl)-3,6,9,12,18-hexaoxaeico-
sanoicacid (1 mM in 100% ethanol) to form a carboxylate-terminated, self-assembled 
monolayer (SAM) on the slide. After rinsing it with 100% ethanol and water in turn, the 
gold chip was dried with compressed air and incubated with a mixture of 0.2 M 
ethyl(dimethylaminopropyl) carbodiimide (EDC) and 0.05 M N-Hydroxysuccinimide 
(NHS) for 15 min to activate the carboxylate groups need for the subsequent 
immobilization of Protein A/G (200 µg/ml, Thermo Scientific) through amide bond 
formation with primary amine groups of Protein A/G. Parallel micro-channels (300 mm x 
20 mm x 10 mm, W x H x L) were formed by sealing the protein A/G-coated gold chip 
with a polydimethylsiloxane (PDMS) slab that was embedded with the channels’ pattern. 
Immobilization of the test Abs was achieved by injecting 2F5 and 4E10 (80 mg/mL) to 
individual channels and incubated for 1 h. Protein A/G captures Abs by their Fc region, 
allowing their unimpeded interactions with antigens. After immobilization of the Abs, the 
PDMS slab was peeled off and the gold chip was rinsed with running buffer and then 
assembled with a mono-channel flow cell over the whole detection region (10 mm x 10 
mm). To prevent non-specific adsorption, the chip was blocked with BSA (5 mg/mL) 
before further analysis. The running buffer and dilution buffer of the analyte was 1xPBS 
containing 0.02% βDDM. In sequential runs, CTB (the negative control) at 850 nM, 
CTB-MPR at 600 nM and MPR-TMTEV-6His at 840 nM were passed over the ligand 
surface at a flow rate of 1 µl/s, with a 300-sec association and a 600-sec dissociation. The 
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chip was regenerated between runs with H3PO4 (1:200 of 85% w/w) for 100 s followed 
by recoating with the desired antibody. Identical injections over blank protein A/G 
surfaces were subtracted from the data for kinetic analysis. SPRi data consisting of video 
images at 1 s resolution were analyzed with Data Analysis Module software from 
Plexera. The binding curve was analyzed and fitted with 1:1 interaction model with 
Scrubber 2 software (Biologic Software). 
2.6.2 Supporting Tables 
Intensity 
Distribution 
Radius 
(nm) 
Polydispersity 
(%) 
Mw-R 
(kDa) 
Intensity 
(%) 
Mass 
(%) 
Peak 1 4.7±0.1 11.8±0.6 121.0±3.0 963.5±3.5 100.0±0.0 
Supporting Table 2.1. Result from DLS measurement of purified MPR-TM. 
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Intensity 
Distribution 
Radius 
(nm) 
Polydispersity 
(%) 
Mw-R 
(kDa) 
Intensity 
(%) 
Mass 
(%) 
Day 1 
Peak 1 4.6 11.2 118 93.0 100.0 
Peak 2 43.1 11.1 22441 7.0 0.0 
Day 2 
Peak 1 4.6 10.2 118 91.5 100.0 
Peak 2 34.7 10.0 13543 8.5 0.0 
Day 3 
Peak 1 4.7 22.6 127 95.3 100.0 
Peak 2 47.4 19.6 28120 4.3 0.0 
Peak 3 1062.0 21.9 40520700 0.4 0.0 
Day 4 
Peak 1 4.8 23.3 130 93.9 100.0 
Peak 2 42.2 22.9 20264 5.5 0.0 
Peak 3 259.5 16.7 1498970 0.7 0.0 
Day 7 
Peak 1 4.7 18.5 126 91.9 100.0 
Peak 2 35.6 16.5 14334 7.3 0.0 
Peak 3 743.5 13.8 17596700 0.8 0.0 
Day 10 
Peak 1 4.6 16.8 121 91.4 100.0 
Peak 2 42.1 12.6 21277 8.3 0.0 
Peak 3 690.2 11.4 14782400 0.3 0.0 
Supporting Table 2.2. DLS measurements of purified MPR-TM subjected to prolonged 
incubation at 4 °C. Samples were taken at the indicated time points 
 
 
 
 
 
 
 
 
 
 
	   48 
2.6.3 Supporting Figures 
 
Supporting Fig. 2.1.  DLS measurement of the stability of purified MPR-TM. Purified 
MPR-TM was kept at 4 °C, and DLS measurments were carried out at day 1, 2, 3, 4, 7 
and 10. The result shows that MPR-TM remains monodisperse for at least 10 days.  
	   49 
CHAPTER 3 
BIOPHYSICAL CHARACTERIZATION OF A VACCINE CANDIDATE AGAINST 
HIV-1: THE TRANSMEMBRANE AND MEMBRANE PROXIMAL DOMAINS OF 
HIV-1 GP41 AS A MALTOSE BINDING PROTEIN FUSION 
3.1 Abstract  
The membrane proximal region (MPR, residues 649-683) and transmembrane 
domain (TMD, residues 684-705) of the gp41 subunit of HIV-1’s envelope protein are 
highly conserved and are important in viral mucosal transmission, virus attachment and 
membrane fusion with target cells. Several structures of the trimeric membrane proximal 
external region (residues 662-683) of MPR have been reported at the atomic level; 
however, the atomic structure of TMD still remains unknown. To elucidate the structure 
of both MPR and TMD, we expressed the region spanning both domains MPR-TM 
(residues 649-705) in Escherichia coli as a fusion protein with E. coli’s maltose binding 
protein (MBP). MPR-TM was initially fused to the C-terminus of MBP via a 42 aa-long 
linker containing a TEV protease recognition site (MBP-linker-MPR-TM). The purified 
MBP-linker-MPR-TM protein was biophysically characterized by size exclusion 
chromatography, CD spectroscopy and dynamic light scattering. Our results indicated 
that the purified MBP-linker-MPR-TM protein was a monodisperse and stable candidate 
for crystallization. However, crystals of the MBP-linker-MPR-TM protein could not be 
obtained in extensive crystallization screens. It is possible that the 42 residue-long linker 
between MBP and MPR-TM was interfering with crystal formation. To test this 
hypothesis the 42 residue-long linker was replaced with three alanine residues. This 
fusion protein, MBP-AAA-MPR-TM, was similarly purified and characterized. The 
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crystallization experiments of MBP-AAA-MPR-TM are currently undergoing. 
Significantly, both MBP-linker-MPR-TM and MBP-AAA-MPR-TM protein strongly 
interacted with broadly neutralizing monoclonal antibodies 2F5 and 4E10. With epitopes 
accessible to the broadly neutralizing antibodies, MBP/MPR-TM recombinant proteins 
may be in an immunologically relevant conformation mimicking a pre-hairpin 
intermediate of gp41.  
3.2 Introduction 
The transmembrane (TM) domain of HIV-1 gp41 is one of the most highly 
conserved regions of the envelope glycoprotein (Env) of HIV-1 (Shang et al., 2008; 
Checkley et al., 2011). This region is involved in many essential biological functions 
(recently reviewed by Steckbeck and co-workers (Steckbeck et al., 2013)). The primary 
role of gp41 TM domain is to anchor Env in both viral and cellular membranes (Gabuzda 
et al., 1991). It has been recently reported that the TM domain induces lipid mixing and 
associates with the fusion peptide (FP) of HIV-1 gp41 during the viral fusion process 
(Reuven et al., 2012). The gp41 TM peptide was able to inhibit virus-cell fusion because 
it associates strongly with FP and thus may interfere with FP’s inserting into the target 
cell membrane, which makes gp41 TM peptide a new fascinating HIV-1 entry inhibitor 
(Reuven et al., 2012). Additionally, the gp41 TM domain shares a motif with the α 
subunit of the T-cell receptor (TCR) TM domain (Checkley et al., 2011). The gp41 TM 
peptide co-localizes with CD3 in the TCR complex and inhibits T cell proliferation in 
vitro, which could be one of the strategies that the HIV-1 virus has developed to evade 
the immune response (Cohen et al., 2010).  
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Mao et al. reported a 6-Å structure of the membrane-bound HIV-1 envelope 
glycoprotein trimer in its uncleaved state by using cryo-electron microscopy (EM), which 
included the TM domain of gp41 (Mao et al., 2013). This is the only structural 
information of the TM domain of gp41 reported so far. The atomic structure of the gp41 
TM domain remains unknown perhaps due to its high hydrophobicity making its 
expression, purification and crystallization difficult. The traditional model of the gp41 
TM domain is a single membrane-spanning α-helix (residues 684-705) followed by a 
intracytoplasmic C-terminal tail (CTT) (Checkley et al., 2011). An alternative model was 
proposed by Hollier and Dimmock (Hollier and Dimmock, 2005) to explain the 
observation that an epitope in the C-terminal tail of HIV-1 gp41 (the so-called Kennedy 
epitope (Hilf and Dutzler, 2008)) is extracellulary exposed under some conditions. To 
account for the drastic change in the membrane topology necessary for the exposure of 
the Kennedy epitope, Hollier and Dimmock speculatively suggested that the 
transmembrane region assumes a different secondary structure consisting of three 
membrane-spanning β-sheets under certain conditions (Hollier and Dimmock, 2005). 
Another highly conserved segment of HIV-1 gp41 is the membrane proximal 
region (MPR, residues 650-685) (Miyauchi et al., 2005; Checkley et al., 2011), which 
contains the membrane proximal external region (MPER, residues 662-683) and part of 
the C-terminal heptad repeat region (CHR, residues 650-661) of HIV-1 gp41. HIV-1 
gp41 is essential in transcytosis, a process leading to mucosal transmission of the virus 
(Bomsel et al., 2011; Shen et al., 2011; Puryear and Gummuluru, 2013). Transcytosis is 
initiated when gp41 binds to the epithelial glycosphingolipid galactosyl ceramide (Gal 
Cer), the epithelial cell receptor for HIV (Alfsen et al., 2001).  The minimal region 
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required for gp41 to bind Gal Cer is the membrane proximal region (MPR, residues 650-
685) (Alfsen and Bomsel, 2002). Furthermore, MPR is the target of secretory IgAs, 
which block HIV-1 transcytosis by neutralizing gp41 binding to Gal Cer (Devito et al., 
2000; Tudor et al., 2009).  Significantly, epitopes in the MPER are recognized by three 
broadly neutralizing antibodies 2F5 (Purtscher et al., 1994), 4E10 (Zwick et al., 2001) 
and 10E8 (Huang et al., 2012).  
HIV-1 gp41 mediates the membrane fusion between target cell and virus through 
its own conformational change: native trimer prior to the interaction between gp120 and 
CD4, pre-hairpin intermediate and postfusion trimer of hairpins (or a six-helix bundle) 
(Chan and Kim, 1998).  Structures of trimeric MPER have been solved in the pre-fusion 
(Pancera et al., 2014) and postfusion conformations (a six-helix bundle) (Buzon et al., 
2010; Shi et al., 2010). However, both of them could not be recognized by the broadly 
neutralizing antibodies 2F5 or 4E10. Another structure of trimeric MPER has been solved 
in the postfusion state (a six-helix bundle) containing a shortened NHR (HR1) region, 
which left MPER accessible to 2F5 antibody (Shi et al., 2010). More recently, Reardon et 
al. reported a trimeric MPER structure solved by NMR spectroscopy in a putative pre-
fusion intermediate state (a three-helix bundle) (Reardon et al., 2014). In their structure, 
the N termini of the MPER helices are closely associated with each other while the C 
termini gradually separate, which leaves space for antibody binding. However, in their 
construct, MPER was fused to the C terminus of a 27-residue trimerization domain from 
bacteriophage T4 fibritin (the foldon domain). Although Reardon et al. reported that 
MPER was linked to the foldon motif through a flexible linker GSSG, which is intended 
to minimize the effect of the structured trimerization motif on the conformation and 
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dynamics of MPER, it is still not experimentally confirmed that MPER forms a trimer in 
the pre-fusion intermediate form without the effect of the trimerization motif. Moreover, 
the tight association of the MPER trimer at N terminus could be due to its proximity to 
the tight foldon motif while C terminus of the MPER trimer separated from each other 
because it has less effect from the trimerization motif. To better understand HIV-1 gp41 
and instruct design of vaccines and therapeutics against HIV-1, elucidating the structure 
of the gp41 MPR and TM domains is required. 
Mistic, a Bacillus subtilis integral membrane protein (Roosild et al., 2005), was 
previously used as a fusion partner in our laboratory to overexpress MPR-TM of HIV-1 
gp41, where the fusion partner Mistic was removed for crystallization (Gong et al., 2014). 
However, no crystals were obtained even after extensive crystallization screens. It may be 
due to the highly hydrophobic property of MPR-TM and/or lack of crystal contacts 
between MPR-TM molecules. In this work reported here, a novel construct was designed 
to overexpress MPR-TM as a maltose binding protein (MBP) fusion. MBP is a 
commonly used fusion partner, capable of improving the solubility and expression level 
of the target protein (Kapust and Waugh, 1999; Kobe et al., 1999; Do et al., 2014; 
Nguyen et al., 2014; Raran-Kurussi and Waugh, 2014). MBP may function as a chaperon 
to assist the correct folding of the target proteins in active form (Kapust and Waugh, 
1999). Furthermore, MBP may provide a large hydrophilic interaction surface for 
formation of crystal lattice contacts thereby facilitating crystal formation (Moon et al., 
2010). Structures of dozens of MBP recombinant proteins have been solved at atomic 
resolution by X-ray structure analysis in the past decades (reviewed in Refs. (Smyth et 
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al., 2003; Moon et al., 2010)), which indicated that MBP could be used as a fusion 
partner for structural studies.  
In the present study, we reported the expression, purification and biophysical 
characterization of MPR-TM (residues 649 to 705) as a fusion to the C terminus of 
8xHis-tagged MBP for structural determination by X-ray crystallography. Surface 
plasmon resonance (SPR) was used to test if the epitope on the purified protein was 
exposed and could be recognized by the broadly neutralizing mAbs 2F5 and 4E10. 
Crystals of the MBP/MPR-TM recombinant protein could not be obtained when MPR-
TM was fused to the C-terminus of MBP via a 42-residue linker. The linker was changed 
to three alanine residues (MBP-AAA-MPR-TM) and crystallization experiments are 
undergoing.   
3.3 Materials and Methods 
3.3.1 Cloning and Expression of MBP-linker-MPR-TM and MBP-AAA-MPR-TM 
The coding region of gp41 MPR-TM flanked by a TEV cleavage site was 
subcloned from pMistic-MPR-TM (Gong et al., 2014) into the pCR8/GM/Topo vector 
(Invitrogen, Carlsbad, CA), sequence-verified and shuttled into the pVP16 destination 
vector (Thao et al., 2004) by Gateway® recombination cloning (Invitrogen, Carlsbad, 
CA). An aliquot of the LR reaction was used to transform One Shot® TOP10 chemically 
competent E. coli cells following the protocol provided by the manufacturer (Invitrogen, 
Carlsbad, CA). Recombinant clones were selected on LB agar plates supplemented with 
100 µg/mL of ampicillin. Plasmid DNA was isolated from several colonies using 
QIAGEN Plasmid Mini Kit (QIAGEN, Valencia, CA) and digested with EcoRI and KpnI 
(Promega, Madison, WI) to confirm the presence of the insert into pVP16. The verified 
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recombinant expression vector of MBP-linker-MPR-TM was further transformed into 
NEB Express competent cells (New England Biolabs, Ipswich, MA), an enhanced BL21 
derivative that allows inducible recombinant protein expression from T5 and other non-
T7 promoters. Recombinant clones of MBP-linker-MPR-TM were selected on LB plates 
supplemented with 100 µg/mL of ampicillin. 
To construct the gene encoding MBP-AAA-MPR-TM, a 153 bp BglII and SalI 
restriction fragment that encompasses a region of the MBP-linker-MPR-TM coding 
sequence that encodes the long linker and a TEV protease recognition site (spanning 
EALKDAQ…ENLYFQG, Supporting Fig. 3.1) was replaced with a DNA sequence that 
encodes the protein sequence AALAAAQTNAAA. This cloning was accomplished with 
the following PCR reactions using Takara PrimeSTAR Max DNA Polymerase (Clontech, 
Mountain View, CA; see Supporting Table 3.1 (page 79) for the primer sequences). 
PCR1 used primers MBP-MPR-fuseF1 and insert1-PCR1R, and template MBP-linker-
MPR-TM; PCR2 used primers MBP-MPR-fuseF1 and insert1-PCR2R, and template 
PCR1; PCR3 used primers insert2-PCR1F and MBP-MPR-fuseR1, and template MBP-
linker-MPR-TM; PCR4 used primers MBP-MPR-fuseF2 and MBP-MPR-fuseR1, and 
template PCR2. The products of PCR3 and PCR4 were simultaneously inserted into 
BglII- and SalI-digested MBP-linker-MPR-TM using the ligation-independent InFusion 
HD Cloning Plus system (Clontech) (Hamilton et al., 2007). DNA sequence confirmation 
was performed at the School of Life Sciences DNA Laboratory at Arizona State 
University. Vectors and their sequences have been deposited and are available from the 
PSI:Biology-Materials Repository at DNASU (http://dnasu.org) (Seiler et al., 2014). The 
verified recombinant expression vector of MBP-AAA-MPR-TM was further transformed 
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into BL21(DE3) competent cells (Invitrogen).  Recombinant clones of MBP-AAA-MPR-
TM were selected on LB plates supplemented with 100 µg/mL of ampicillin.  
Bacterial overexpression of both fusion proteins was done as follows. A single 
bacterial colony was used to inoculate 100 mL pre-culture in LB containing 100 µg/mL 
of ampicillin in a shaker-incubator (37 °C, 200 rpm) overnight. This culture was used to 
inoculate 3 L of LB broth containing 100 µg/mL of ampicillin at a dilution ration of 1:30. 
Cells were grown until the culture density reached OD600 between 0.6 and 0.8. Protein 
expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a 
final concentration of 500 µM and continued incubation for additional 4 h. Bacteria were 
harvested by centrifugation (5000 ×g, 10 min, 4 °C) and cell pellets (12-14 g fresh weight 
per 3 L culture) were then stored at -80 °C until further use. 
3.3.2 Preparation of the Crude Membrane Fractions of MBP-linker-MPR-TM and 
MBP-AAA-MPR-TM 
Preparation procedures of the crude membrane fractions of MBP-linker-MPR-TM 
and MBP-AAA-MPR-TM were same. Cell pellets stored at -80 °C were thawed and re-
suspended in ice-cold phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4 with 1× EDTA-free protease inhibitor (Sigma). 
100 mL of PBS buffer containing 1× EDTA-free protease inhibitor (Sigma) was used to 
re-suspend per 15 grams of wet cell pellet. The suspension was disrupted by ultrasonic 
homogenizer (Model 300 V/T, Biologics) at 150 W and 10 kHz for 1 min on and 1 min 
off while kept on ice. This step was repeated three times in total. The cell lysate was 
centrifuged at 20,000 × g for 20 min at 4 °C. The supernatant was discarded and the 
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pellet, containing the membrane fraction, peptidoglycan cell wall and other aqueous-
insoluble material was stored at -80 °C overnight.  
3.3.3 Detergent Solublization of MBP-linker-MPR-TM and MBP-AAA-MPR-TM 
The frozen crude membrane fraction of MBP-linker-MPR-TM was thawed and 
resuspended in ice-cold PBS buffer with 1× EDTA-free protease inhibitor (Sigma, 
S8830). 100 mL of PBS buffer containing 1× EDTA-free protease inhibitor (Sigma) was 
used to re-suspend per 15 grams of crude membrane fraction. Detergent screens were 
conducted by adding the following detergents to 1% (w/v) final concentration: 
lauryldimethylamine-oxide (LDAO), n-decyl-β-D-maltoside (β-DM), and n-dodecyl-β-D-
maltoside (β-DDM). These suspensions were incubated at 4 °C for 2 h. Screening for the 
optimal length of time required for efficient detergent extractions was done essentially as 
described above except that the incubation time was varied among 0.5 h, 1 h, 2 h and 3 h 
respectively. Following their incubation, the suspensions were centrifuged at 20,000 ×g 
for 20 min and the supernatant liquid, which contained detergent-soluble proteins, was 
then used for further analyses. Large scale detergent extractions of both MBP-linker-
MPR-TM and MBP-AAA-MPR-TM were performed with 1% βDDM at 4 °C for 1 h. 
3.3.4 Purification of MBP-linker-MPR-TM and MBP-AAA-MPR-TM 
Purification procedures of MBP-linker-MPR-TM and MBP-AAA-MPR-TM were 
same. The detergent-solubilized proteins were purified by metal-affinity FPLC using 
nickel-nitrilotriacetic acid (Ni-NTA) Superflow column (QIAGEN). The Ni-NTA 
Superflow resin was manually packed into the Tricon Empty 10/100 column (GE 
Healthcare) with a bed volume of about 8 ml. The columns were equilibrated with buffer 
A (500 mM NaCl, 20 mM bicine pH 8.0 and 0.05% β-DDM). The detergent soluble 
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fraction was injected onto the Ni-NTA Superflow column by a 10 mL superloop (GE 
Healthcare) and washed with buffer A until the A280 was stable below 10 mAu. To 
remove non-specifically-bound proteins, the column was then washed with 2% buffer B 
(Buffer A with 500 mM imidazole; final concentration of imidazole was 10 mM) until the 
A280 was stable below 20 mAu. Specifically-bound proteins were eluted off the column 
by application of a linear gradient of buffer B from 2% to 50% in 25 min at 1 mL/min. 
The eluted proteins were concentrated to 10-20 mg/mL using concentrators (100-kDa 
cutoff polyethersulfone membrane, Sartorius). Concentrated proteins were then subjected 
to size exclusion chromatography (SEC) using a Superdex-200 HR 10/300 gel filtration 
column (GE Healthcare) in SEC buffer (20 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.015% 
β-DDM). The Superdex-200 column was calibrated using standards aprotinin (6.5 kDa), 
RNase A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 
kDa), aldolase (158 kDa) and ferritin (440 kDa). Protein purity was analyzed by SDS-
PAGE. 
The protein concentration of MBP-linker-MPR-TM and MBP-AAA-MPR-TM 
were determined spectrophotometrically at 280 nm using extinction coefficients of 
98,290 cm-1M-1 and 94,450 cm-1M-1, respectively (extinction coefficients were obtained 
using Peptide Property Calculator at http://www.basic.northwestern.edu/biotools/-
proteincalc.html). 
3.3.5 SDS-PAGE, Silver Stain, Immunoblot Detection and Matrix-Assisted Laser 
Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) 
Proteins were resolved by SDS-PAGE and gels were either silver stained or 
subjected to immunoblotting as previously described (Gong et al., 2014). Briefly, SDS-
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PAGE was performed with Tricine-SDS gels with 4% stacking and 8% separating gels 
respectively. The primary antibody (1:2000 dilution) used in immunoblots was BSA-free 
Penta·His antibody (QIAGEN) and the secondary antibody (1:2000 dilution) was goat 
anti-mouse IgG-HRP (Invitrogen). MALDI-TOF-MS was performed as previously 
described (Gong et al., 2014). 
3.3.6 Circular Dichroism (CD) and Dynamic Light Scattering (DLS) Measurements 
The CD spectra of purified sample were measured by A JASCO J-710 CD 
spectropolarimeter and DLS measurements were carried out using DynaPro NanoStar 
M3300 from Wyatt as previously described (Gong et al., 2014). 
In order to study the effect of ionic strength on the secondary structure, the protein 
sample was concentrated to 5 mg/mL as described above and then diluted by 20 times 
into buffers containing 20 mM Tris-HCl, pH 7.5, 0.02% β-DDM and 0, 20, 50, 100, 150, 
200, 250 or 300 mM NaCl. In order to identify the effect of pH on the secondary 
structure, the 5 mg/mL of protein sample was diluted by 20 times into buffers containing 
150 mM NaCl, 0.02% β-DDM and at pH 6.5, 7.0, 7.5, 8.0 or 8.5. Protein samples were 
incubated in the buffer overnight before CD measurements. 
Analysis of the secondary structure content based on CD data was carried out 
using the CDPro software package (Sreerama and Woody, 2000). Three methods 
CDSSTR (Compton and Johnson, 1986; Manavalan and Johnson, 1987; Sreerama and 
Woody, 2000), CONTIN/LL (Provencher and Glockner, 1981; Vanstokkum et al., 1990), 
and SELCON3 (Sreerama and Woody, 1993, 2000) were run using a protein reference set 
with 43 soluble proteins and 13 membrane proteins (SMP56) (Sreerama and Woody, 
2000). The average and standard deviation of the results from these three methods were 
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calculated.  
For thermal denaturation measurements monitored by CD spectroscopy, the CD 
signal at 220 nm was recorded from 15 to 90 °C with a temperature change of slope at a 
rate of 2 °C/min. The apparent midpoint temperature of the transition was calculated from 
the first derivative of the thermal melting curve.  
3.3.7 Surface Plasma Resonance (SPR) 
All experiments were performed in quadruplicate on a KX5 Surface Plasmon 
Resonance Imaging (SPRi) System (Plexera) as previously described (Gong et al., 2014). 
The mAbs 2F5 and 4E10 were immobilized onto the surface of the gold chip (Plexera). 
MBP (fractions A2 from SEC purification, Fig. 3.1C) at 240 nM was used as a negative 
control. The purified MBP-linker-MPR-TM protein at 187 nM and MBP-AAA-MPR-TM 
protein at 205 nM were measured respectively.  
3.4 Results and Discussion 
3.4.1 Cloning and Expression of MBP-linker-MPR-TM 
In order to improve the expression level and solubility of the membrane proximal 
region and transmembrane (MPR-TM) domains of HIV-1 gp41, MPR-TM was fused to 
the C terminus of the maltose binding protein (MBP) by a 42 aa-long linker containing a 
tobacco etch virus (TEV) protease cleavage site (Supporting Fig. 3.1). An 8xHis-tag was 
cloned onto the N-terminus of MBP for purification purpose (Supporting Fig. 3.1). The 
MBP-linker-MPR-TM recombinant protein was expressed in NEB Express E. coli, a 
BL21 derivative-strain as described in Materials and Methods.     
3.4.2 Detergent Solublization of MBP-linker-MPR-TM  
The expressed cells were lysed by ultrasonic homogenizer as described in 
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Materials and Methods and then pelleted by centrifugation. The homogenized cell lysate 
prior to centrifugation and the supernatant containing water-soluble proteins after 
centrifugation were analyzed by anti-His immunoblot. A small portion of MBP-linker-
MPR-TM protein was found to be in the supernatant (Supporting Fig. 3.2A (page 79)). 
Most of the fusion protein, however, was found in the pellet, which contained the 
membrane fraction, peptidoglycan cell wall and other water-insoluble material, and had 
to be extracted by detergents. To establish the optimal solubilization conditions, we have 
tested three different detergents: 1% LDAO, 1% β-DM and 1% β-DDM. The three 
detergents were able to extract the majority of the MBP-linker-MPR-TM protein from the 
pellet and their extraction efficiencies were similar as judged by immunoblot analysis 
(Supporting Fig. 3.2B). β-DDM was chosen for future purification because it has been 
widely and successfully used in crystallization of membrane proteins (Newstead et al., 
2008).  
In order to determine the time needed for efficient detergent extraction, crude 
membrane suspension solution was incubated in 1% βDDM at 4 °C for 0.5 h, 1 h, 2 h and 
3 h respectively. Our results showed that 1 h incubation was sufficient to extract the 
majority of the MBP-linker-MPR-TM protein. Incubation for 2 h and 3 h did not 
significantly increase the extraction efficiency (Supporting Fig. 3.2C). Therefore, crude 
membrane suspension solution was incubated in 1% β-DDM at 4 °C for 1 h for future 
purification. 
3.4.3 Purification of MBP-linker-MPR-TM  
Purification of βDDM-solubilized MBP-linker-MPR-TM protein was accom-
plished by FPLC-connected Ni-affinity chromatography followed by size exclusion 
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chromate-graphy (SEC) in presence of βDDM. A single elution peak was eluted from the 
Ni-affinity chromatogram by a linear increasing gradient of 10 to 250 mM imidazole 
(Fig. 3.1A). The flowthrough and elution peaks were collected and analyzed by SDS-
PAGE (Fig. 3.1B). Two protein bands were identified: one above the 50 kDa marker and 
the other below the 50 kDa marker (Fig. 3.1B). These two proteins were further 
successfully separated by SEC (Superdex 200) (Fig. 3.1C) and analyzed by SDS-PAGE 
analysis (Fig. 3.1D). Both bands were recognized by anti-His antibodies (Fig. 3.1D), 
indicative of an intact 8xHis tag. MALDI-TOF MS analysis demonstrated that SEC peak 
A1 contains a protein of 53,319 Da (Fig. 3.2A), possibly representing the MBP-linker-
MPR-TM fusion protein (theoretical molecular weight: 53,389 Da). The signal at m/z 
26,641 is likely to correspond to MBP-linker-MPR-TM charged with two protons. Peak 
A2 from SEC purification contained proteins with masses ranging from 43,818 Da to 
45,814 Da (Fig. 3.2B). The theoretical molecular weight of the MBP itself is 41,694 Da 
(Fig. 3.2C). MBP including the linker would have a molecular weight of 46,376 Da (Fig. 
3.2C). Therefore, proteins eluted in SEC peak A2 represent a number of C-terminally 
truncated versions of the recombinant fusion protein, which includes intact MBP (Fig. 
3.1C).  
The protein eluted in SEC peak A1 (Fig. 3.1C) was used for further analyses. 
About 60 mg of pure MBP-linker-MPR-TM protein was obtained from 1 liter of LB cell 
culture. 
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Fig. 3.1. Purification of MBP-linker-MPR-TM. (A) Ni-affinity chromatogram of the 
βDDM extraction. Blue curve: UV absorbance at 280 nm; green curve: percentage of 
buffer B. (B) SDS-PAGE analysis of the flowthrough peaks and elution peak of the Ni-
affinity chromatography. (C) SEC of the elution from Ni-affinity chromatography. Blue 
curve: UV absorbance at 280 nm. Peak A1 eluted at 11.09 mL and peak A2 eluted at 
16.33 mL. (D) Silver stained SDS-PAGE (left) and anti-His Western blot (right) analysis 
of the peak A1 and A2 from SEC. 
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Fig. 3.2. Elutions from SEC were analyzed by MALDI-TOF MS. (A) MALDI-TOF MS 
analysis of the peak A1 from SEC (Fig. 3.1C). (B) MALDI-TOF MS analysis of the peak 
A2 from SEC (Fig. 3.1C). (C) Schematic representation of the MBP-linker-MPR-TM 
protein and molecular weight of different protein fragments. Residues 414-420 in green: 
TEV protease recognition site. 
 
3.4.4 MBP-linker-MPR-TM Forms Oligomers  
SDS-PAGE and MALDI-TOF MS analysis can only be used to determine the 
molecular weight of the monomeric MBP-linker-MPR-TM because the proteins were 
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denatured and lost their structural integrity and oligomeric state in these two analysis 
methods. The molecular weight of MBP-linker-MPR-TM in its detergent solubilized state 
was analyzed by analytical SEC and dynamic light scattering (DLS).  
The elution fraction from Ni-affinity chromatography purification were analyzed 
by analytical SEC (Fig. 3.1C). Based on the standard curve calibration, the A2 SEC peak 
(Fig 3.1C, centering at 16.33 mL) corresponded to proteins with MW of <50 kDa, which 
indicated that the various partially truncated fusion proteins containing intact MBP 
remain monomeric as previously reported for MBP (Spurlino et al., 1991). The A1 SEC 
peak (Fig. 1B, centering at 11.09 mL) corresponded to proteins with MW of ~470 kDa 
based on our calibration. Considering the proteins are embedded in large β-DDM 
micelles, the exact oligomeric state is difficult to assess, but it is likely at least a hexamer. 
Previous studies demonstrated that MBP by itself is a monomer (Spurlino et al., 1991) 
but recombinant MBP fusion proteins may form oligomers depending on the nature of the 
fusion partner (Kobe et al., 1999; Ke et al., 2012; Tan et al., 2013). Our SEC results 
therefore provide an indication that it is the MPR-TM that is responsible for the 
oligomerization of MBP-linker-MPR-TM.  
The size of a protein-detergent micelle estimated by SEC provides just a rough 
estimation of its size (Andrew, 2006). DLS was utilized in addition to estimate the 
molecular weight of MBP-linker-MPR-TM in form of the protein-detergent complex 
(Fig. 3.3). The Stokes radius of the detergent-protein complex was determined to be 7.7 ± 
1.0 nm, which corresponded to a molecular mass of about 400 kDa (Supporting table 
3.2). This result is slightly different from the estimation by SEC (~470 kDa). Please note 
that both SEC and DLS can be used to roughly estimate the size of molecules in solution, 
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but the estimation by neither of them is accurate for membrane proteins because both 
DLS and SEC assume a spherical particle that is very likely not the case for our fusion 
protein. The most important function of DLS in our study is to measure the sample’s 
polydispersity distribution, which is the standard deviation of the histogram that refers to 
the width of the peak (Chu, 1970). The percent polydispersity (%Polydispersity) is the 
polydispersity divided by the estimated hydrodynamic radius multiplied by 100. The 
level of homogeneity is considered high when the percent polydispersity is less than 15% 
(Proteau et al., 2010). As shown in Figure 3.3 and Supporting Table 3.2, the percent 
polydispersity of the peak is 13.4% (Supporting Table 3.2), which indicated that the 
purified MBP-linker-MPR-TM is a monodisperse candidate for crystallization. It is 
concluded from the SEC and DLS analysis that MBP-linker-MPR-TM formed an 
oligomer in the presence of detergent.   
 
Fig. 3.3. DLS measurement of the purified MBP-linker-MPR-TM protein showed one 
monodisperse peak at 7.7 ± 1.0 nm. 
 
3.4.5 Secondary Structure Estimation of MBP-linker-MPR-TM by Circular 
Dichroism (CD) Spectroscopy 
It is essential to test if the purified MBP-linker-MPR-TM is folded well by CD 
before carrying out crystallization screens. The result of CD measurement (Fig. 3.4A) 
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displayed one positive band at 193 nm and two negative bands at 208 and 222 nm, which 
is characteristic of a protein with a large fraction of α-helices (Greenfield, 2006). 
Analysis of the secondary structure content of MBP-linker-MPR-TM by CDPro provided 
the following values: 39.3 ± 2.3% α-helix and 13.5 ± 1.8% β-sheet. Comparison of the 
CD spectrum of MBP (fraction A2 in Fig. 3.1C) with that of MBP-linker-MPR-TM 
(fraction A1 in Fig. 3.1C) demonstrated that the two minima of MBP-linker-MPR-TM 
were slightly lower than that of MBP (Supporting Fig. 3.3, page 79). Analysis of the 
secondary structure content of MBP by CDPro showed that MBP contained 33.0 ± 2.6% 
α-helix and 15.2 ± 2.4% β-sheet. The higher α-helix content in MBP-linker-MPR-TM 
might be due to the presence of MPR-TM. The crystal structure of the pre-fusion and 
post-fusion HIV-1 gp41 indicate that the MPR region in these status may form an α-helix 
(Buzon et al., 2010; Shi et al., 2010; Pancera et al., 2014) and the cryo-EM structure of 
the uncleaved HIV-1 envelope glycoprotein indicate that the TM region may also be 
helical in the complex (Mao et al., 2013). CD measurements here function as a quality 
control of the purified protein sample to make sure that the protein is well folded, which 
is a prerequisite condition prior to crystallization screens.  
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Fig. 3.4. CD spectra of MBP-linker-MPR-TM. (A) CD spectrum of MBP-linker-MPR-
TM displayed one positive band at 193 nm and two negative bands at 208 and 222 nm, 
which is characteristic for α-helical proteins. Buffer: 100 mM NaF, 20 mM NaH2PO4, pH 
7.5 and 0.02% βDDM. Protein concentration was 0.26 mg/mL. (B) Thermal denaturation 
curve of MBP-linker-MPR-TM measured at 220 nm and at a rate of temperature change 
of 2 °C/min. The apparent midpoint “denaturation” temperature of the protein was 50 °C. 
Protein concentration was 0.5 mg/mL. (C) Effect of ionic strength on the secondary 
structure of MBP-linker-MPR-TM. CD measurements were performed in 20 mM Tris, 
pH 7.5, 0.02% βDDM containing 0 to 300 mM NaCl. (D) Effect of pH on the secondary 
structure of MBP-linker-MPR-TM. CD spectra were recorded in 150 mM NaCl, 0.02% 
βDDM at pH from 6.5 to 8.5. 
 
3.4.6 Thermal Stability of MBP-linker-MPR-TM 
In order to estimate the thermal stability of the MBP-linker-MPR-TM protein and 
to guide decisions of the optimal temperature at which crystallization screens should be 
performed, CD spectroscopy was used to measure the apparent midpoint “denaturation” 
temperature of MBP-linker-MPR-TM. The CD spectra were recorded at 220 nm from 15 
to 90 °C with a temperature change slope at 2 °C/min. The result showed that the 
apparent midpoint “denaturation” temperature of the sample was 50 °C (Fig. 3.4B), 
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which indicated good thermal stability. According to the melting curve obtained (Fig. 
3.4B), the MBP-linker-MPR-TM protein would not denature below 45 °C. Therefore, 
crystallization screens of MBP-linker-MPR-TM could be performed at room temperature 
or lower temperatures.  
3.4.7 Effect of Ionic Strength and pH on the Secondary Structure of MBP-Linker-
MPR-TM 
Ionic strength and pH are two important parameters which could be adjusted in 
crystallization screens to promote the crystal formation. We aimed to investigate the 
effect of ionic strength and pH on the secondary structure of the MBP-linker-MPR-TM 
protein to determine the range in which these two parameters could be adjusted to ensure 
that the protein would be correctly folded under crystallization conditions. We used CD 
measurements under various conditions of pH and ionic composition of the medium to 
determine how they would affect the secondary structure of MBP-linker-MPR-TM. The 
purified MBP-linker-MPR-TM protein was concentrated to 5 mg/mL, diluted into buffers 
containing 0 to 300 mM NaCl at pH 7.5 to test the effects of ionic strength (Fig. 3.4C), or 
diluted into buffers containing 150 mM NaCl at different pH values ranging from 6.5 to 
8.5 to test the effect of pH  (Fig. 3.4D). The samples were equilibrated overnight at 4 °C 
and CD spectra were measured the next day. 
The CD spectra of MBP-linker-MPR-TM in buffers containing different ionic 
strength (Fig. 3.4C) and pH (Fig. 3.4D) were very similar: they all showed negative 
bands at 208 and 222 nm of almost the same molar ellipticity (deg. · cm2/dmol). Our 
results indicate that the fusion protein MBP-linker-MPR-TM is stable under all tested 
conditions and crystallization screens of MBP-linker-MPR-TM could potentially be 
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carried out at a large ionic strength and pH range, at which the protein will not be 
denatured. 
 3.4.8 MBP-linker-MPR-TM is Stable at High Protein Concentration   
Crystallization screens often start with a protein concentration at 10 mg/mL 
although the optimal protein concentration depends on the molecular weight of the 
protein, the stability of the protein at high concentration and some other properties. Here 
SEC and DLS were used to test the stability of MBP-linker-MPR-TM at high protein 
concentration. The protein was concentrated to 10 mg/mL by a 100-kDa cut-off 
concentrator to avoid concentration of the detergent βDDM, whose micelle molecular 
weight is 68 kDa (Gong et al., 2014). The concentrated sample was stored at 4 °C and 
analyzed by SEC and DLS at day 1, 3 and 7 respectively.  
The size exclusion chromatogram (Fig. 3.5A) revealed a main peak eluting at 
about 10 mL and a very small minor peak eluting at 14.5 mL from day 1 to day 7. The 
main peak contained oligomeric MBP-linker-MPR-TM/detergent complex while the 
small minor peak at 14.5 mL might represent the MBP protein. The small minor peak 
increased slightly from day 1 to day 7, which represented 0.4%, 0.7% and 1.5% of the 
total area respectively (insert in Fig. 3.5A), but was still very small compared with the 
main peak after one week storage at 4 °C.  
The DLS measurements (Fig. 3.5BCD and Supporting Table 3.3) revealed a 
narrow peak at 7.1 to 7.6 nm with the percent polydispersity below 12% from day 1 to 
day 7, which indicates that the protein sample is in a monodisperse condition for seven 
days at 4 °C (Fig. 3.5BCD and Supporting Table 3.3). Although a small aggregation peak 
at 90.2 nm was detected on day 7, the aggregation peak represented only 0.1% of the total 
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amount (mass) of the protein because the increase in scattered intensity is proportional to 
r6 (r is the particle radius) (Hoo et al., 2008). In conclusion, 10 mg/mL MBP-linker-MPR-
TM was homogeneous and monodisperse for 7 days and crystallization screens could be 
performed at this concentration. 
 
Fig. 3.5. Stability test of 10 mg/mL MBP-linker-MPR-TM. 10 mg/mL MBP-linker-MPR-
TM was stored at 4 °C and measured by SEC and DLS on day 1, 3 and 7. (A) Stability 
test of 10 mg/mL MBP-linker-MPR-TM by SEC. Insert: magnification of the degradation 
peak, which indicated slight increase of the MBP-linker-MPR-TM degradation from day 
1 to day 7. (B-D) Stability test of 10 mg/mL MBP-linker-MPR-TM by DLS. The protein 
sample was homogeneous and monodisperse for 7 days at 4 °C; only a little protein 
aggregation was detected on day 7. 	  
3.4.9 MBP-linker-MPR-TM is Recognized by the Broadly Neutralizing mAbs 2F5 
and 4E10 
An important feature of gp41 is that it contains the epitopes for broadly 
neutralizing antibodies 2F5 and 4E10, which makes it an attractive target for vaccine 
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design. However, the epitopes for 2F5 and 4E10 cannot bind the antibodies in the pre-
fusion and post-fusion conformations of gp41. HIV-1 gp41 mediates the membrane 
fusion between target cell and virus through its own conformational change: native trimer 
prior to the interaction between gp120 and CD4, pre-hairpin intermediate and postfusion 
trimer of hairpins (or a six-helix bundle) (Chan and Kim, 1998).  It was reported by Frey 
at al that gp41 in its prefusion conformation could not interact with 2F5 or 4E10; gp41 in 
its postfusion conformation binds 2F5 very weakly (Kd ≈ 1.4 µM), while gp41 in its pre-
hairpin intermediate state binds 2F5 and 4E10 very strongly (Kd < 10 nM) (Frey et al., 
2010). Therefore, it is of great interest to measure the binding affinities of MBP-linker-
MPR-TM to 2F5 and 4E10 by surface plasma resonance (SPR), from which the 
conformational information of MPR-TM could be estimated.  
In SPR measurements, mAbs 2F5 and 4E10 were immobilized onto the surface of 
the gold chip. The negative control MBP (fractions A2 from SEC purification, Fig. 3.1B) 
and the purified MBP-linker-MPR-TM protein were passed over the ligand surface to 
measure their binding affinities to 2F5 and 4E10. Identical injections over blank surfaces 
were subtracted from the data for kinetic analysis. The result showed that mAbs 2F5 and 
4E10 bound strongly to MBP-linker-MPR-TM with a KD of 0.5 ± 0.2 nM for the 2F5 Ab 
and a KD of 0.3 ± 0.1 nM for the 4E10 Ab (Fig. 3.6 and Table 3.1). This result strongly 
indicates that MBP-linker-MPR-TM may be in the pre-hairpin intermediate 
conformation, at which stage the epitopes for 2F5 and 4E10 are exposed and are available 
for antibody binding. The weak unspecific binding of 2F5 and 4E10 to the negative 
control MBP (fractions A2 from SEC purification, Fig. 3.1B) may be due to the existence 
of high concentration of maltose (10% maltose) in the antibody solution. However, the 
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binding affinities of MBP-linker-MPR-TM to mAbs 2F5 and 4E10 are much stronger 
than that of MBP with a KD of 674.3 ± 306.9 nM for the 2F5 Ab and a KD of 543.8 ± 
337.7 nM for the 4E10 Ab. Therefore, the strong binding of MBP-linker-MPR-TM to 
mAbs 2F5 and 4E10 is due to the presence of MPR-TM instead of MBP. 
 
Fig. 3.6. Surface plasma resonance (SPR) analysis. 
 
Immobilized ligand Flowing analyte ka, s-1 kd, s-1 KD, nM 
2F5 MBP-linker-MPR-TM 7.0 ± 1.2E4 3.5 ± 1.2E-5 0.5 ± 0.2 
4E10 MBP-linker-MPR-TM 4.8 ± 0.1E4 1.8 ± 0.5E-5 0.3 ± 0.1 
Table 3.1. Association and dissociation rate constants of MBP-linker-MPR-TM derived 
from SPR analysis (Results are average of four independent measurements and are listed 
as in mean ± SD). 
 
3.4.10 Change the Linker of MBP-linker-MPR-TM to Three Alanine Residues 
Extensive crystallization trials with screens of thousands of conditions using both 
vapor diffusion method and liquid cubic phase did not yield crystals of MBP-linker-
MPR-TM with diffraction quality. Similar problems were reported by Center et al., who 
described that crystals could not be obtained when the ectodomain of gp21 (human T cell 
leukemia virus type I transmembrane protein) fused to the C-terminus of MBP via a 
flexible linker containing 25 residues, but were obtained after changing the linker to three 
alanine residues (Center et al., 1998). Their strategy was applied to our study. The 42 aa-
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long linker containing a TEV protease recognition site was replaced by a short three-
alanine linker (Fig. 3.7). In addition, three charged residues at the C-terminus of MBP 
(Glu-370, Lys-373 and Asp-374) were replaced by alanines to avoid potential 
electrostatic repulsion between MBP monomers if MPR-TM forms a trimer (Center et al., 
1998). The new fusion protein was dubbed MBP-AAA-MPR-TM (Fig. 3.7). 
 
Fig. 3.7. Schematic representation of the sequence of MBP-linker-MPR-TM (A) and 
MBP-AAA-MPR-TM (B). Amino acid changes in the C-terminus of MBP are 
underlined. 
 
We employed the purification procedure that was devised for MBP-linker-MPR-
TM to purify MBP-AAA-MPR-TM. Ni-affinity chromatography of MBP-AAA-MPR-
TM resulted in a single band at the expected apparent MW (49 kDa, Fig. 3.8B), unlike 
the case of preparations of the longer-linker fusion protein, which contained prominent 
contaminating degradation products (Fig. 3.1A and B). The purity of the affinity 
chromatography eluate was further demonstrated by a subsequent SEC, which exhibited a 
single peak (Fig. 3.8A). About 60 mg of pure MBP-AAA-MPR-TM protein was obtained 
from 1 liter of bacterial culture. 
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Fig. 3.8. Purification of MBP-AAA-MPR-TM. (A) SEC of the Ni-affinity elution of 
MBP-AAA-MPR-TM. (B) Silver stained SDS-PAGE analysis of Ni-NTA flowthrough, 
Ni-NTA elution and SEC peak A1. 
 
3.4.11 CD, DLS and SPR measurements of MBP-AAA-MPR-TM 
CD spectroscopy measurements showed that the CD spectrum of MBP-AAA-
MPR-TM was very similar to that of MBP-linker-MPR-TM (Fig. 3.9A). Analysis of the 
secondary structure content of MBP-AAA-MPR-TM by CDPro provided the following 
values: 38.8 ± 2.3% α-helix and 13.9 ± 2.6% β-sheet, which is in good agreement with 
the secondary structure content of MBP-linker-MPR-TM (39.3 ± 2.3% α-helix and 13.5 ± 
1.8% β-sheet). These results indicate that changing of the linker to three alanine residues 
did not affect the secondary structure of the recombinant protein.  
DLS analysis displayed one monomeric peak at 7.4 ± 0.8 nm, which corresponded 
to a protein/detergent complex of 360 kDa (Fig. 3.9B and Supporting Table 3.2). The size 
estimation of MBP-AAA-MPR-TM is slightly smaller than that of MBP-linker-MPR-TM 
(7.7 ± 1.0 nm and ~400 kDa, Fig. 3.3 and Supporting Table 3.2), which reflects the 
slightly smaller mass of MBP-AAA-MPR-TM.  
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Fig. 3.9. CD, DLS and SPR measurements of MBP-AAA-MPR-TM. (A) Comparison of 
CD spectra of MBP-linker-MPR-TM and MBP-AAA-MPR-TM. (B) DLS measurement 
of MBP-AAA-MPR-TM showed one monodisperse peak at 7.4 ± 0.8 nm. (C) SPR 
analysis.  
 
Immobilized ligand Flowing analyte ka, s-1 kd, s-1 KD, nM 
2F5 MBP-AAA-MPR-TM 2.1 ± 0.3E4 2.1 ± 0.8E-5 1.0 ± 0.5 
4E10 MBP-AAA-MPR-TM 7.3 ± 1.3E3 3.7 ± 1.8E-6 0.5 ± 0.1 
Table 3.2. Association and dissociation rate constants of MBP-AAA-MPR-TM derived 
from SPR analysis (Results are average of four independent measurements and are listed 
as in mean±SD). 
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As the longer linker could provide more flexibility of the MPR region for binding 
the broadly neutralizing Abs, we conducted SPR measurements to determine if the MBP-
AAA-MPR-TM protein still binds the Abs with high affinity. The SPR result shown in 
Table 3.2 indicated that both 2F5 and 4E10 bind to MBP-AAA-MPR-TM with 
nanomolar to subnanomolar affinities: KD values of 1.0 ± 0.5 nM were determined for 
2F5 Ab and KD values of 0.5 ± 0.1 nM were determined for 4E10 Ab (Fig. 3.9C and 
Table 3.2). It is therefore concluded that MBP-AAA-MPR-TM protein binds 2F5 and 
4E10 Abs with nanomolar to subnanomolar affinities which makes it an excellent 
candidate for vaccine developments against HIV-1. 
3.5 Conclusion 
In summary, we describe here the expression and purification of two recombinant 
protein variants consisting of a fusion between MBP and MPR-TM of HIV-1 gp41. In 
one of these variants, MPR-TM was fused to the C-terminus of MBP via a 42 aa-long 
linker containing a TEV protease recognition site. In the second variant, the long linker 
was replaced by a short and structured peptide consisting of three alanine residues. Both 
proteins were purified to homogeneity and were shown to be stable in solution under 
various conditions and remained monodisperse over time. Both proteins were able to 
strongly interact in solution with the broadly neutralizing mAbs 2F5 and 4E10 with 
nanomolar to subnanomolar affinities, in good agreement with our previously published 
results concerning MPR-TM (Gong et al., 2014). The longer linker variant MBP-linker-
MPR-TM was not amenable to crystallization under exhaustive screening. The 
crystallization experiments of MBP-AAA-MPR-TM are currently undergoing.  
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3.6 Supporting Information 
3.6.1 Supporting Figures 
 
Supporting Fig. 3.1. Amino acid sequence of MBP-linker-MPR-TM. The color scheme 
is as followings: blue, 8His-MBP (residues 1-368); black and green: 42 aa-long linker 
containing a TEV protease recognition site (residues 379-420); green: TEV protease 
recognition site (residues 414-420); red: MPR-TM (residues 421-479). 
 
 
Supporting Fig. 3.2. Anti-His Western blot analysis of the detergent solublization of 
MBP-linker-MPR-TM. (A) A small portion of MBP-linker-MPR-TM protein was found 
to be in the supernatant. (B) Comparison the extract efficiency of different detergents. (C) 
Determination of the time needed for efficient detergent extraction. 
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Supporting Fig. 3.3. Comparison of the CD spectra of MBP and MBP-linker-MPR-TM.  
 
3.6.2 Supporting Tables 
Primer Sequence (5’ to 3’) 
MBP-MPR-fuseF1 CTGATTTATAACAAAGATCTGCTGCCGAACCCG 
insert1-PCR1R CAGGGCTGCATCGACAGTC 
insert1-PCR2R ATTAGTCTGCGCGGCTGCCAGGGCTGCATCGACAGTC 
insert2-PCR1F GCAGCTGCCATGGGATCTCAAACTCAACAAGAGAAG 
MBP-MPR-fuseR1 CGATGGTACCGTCGACGTCCTACAGGCGCGCC 
MBP-MPR-fuseF2 GCCGCGCAGACTAATGCAGCTGCCATGGGATCTC 
Supporting Table 3.1. Primer sequences 
 
Intensity 
Distribution 
Radius 
(nm) 
% Polydispersity 
 
Mw-R 
(kDa) 
% Intensity 
 
% Mass 
 
Peak 1 7.7 ± 0.5 13.4 397  100.0 100.0 
Supporting Table 3.2. DLS measurement of purified MBP-linker-MPR-TM 
 
Intensity 
Distribution 
Radius 
(nm) 
Polydispersity 
(%) 
Mw-R 
(kDa) 
Intensity 
(%) 
Mass 
(%) 
Day 1 
Peak 1 7.5 ± 0.4 10.9 370 100.0 100.0 
Day 3 
Peak 1 7.6 ± 0.4 11.5 385 100.0 100.0 
Day 7 
Peak 1 7.1 ± 0.2 6.1 330 90.5 99.9 
Peak 3 90.2 ± 4.4 9.7 126571 9.5 0.1 
Supporting Table 3.3. DLS measurements of 10 mg/ml MBP-linker-MPR-TM subjected 
to prolonged incubation at 4 °C. Samples were taken at the indicated time points. 
 
Intensity 
Distribution 
Radius 
(nm) 
Polydispersity 
(%) 
Mw-R 
(kDa) 
Intensity 
(%) 
Mass 
(%) 
Peak 1 7.4 ± 0.4 10.2 360 100.0 100.0 
Supporting Table 3.4. DLS measurement of purified MBP-AAA-MPR-TM 
	   80 
CHAPTER 4 
CRYSTALLIZATION AND CRYSTALLOGRAPHIC ANALYSIS OF CRYSTALS 
OBTAINED FROM A SOLUTION OF MBP-AAA-MPR-TM 
4.1 Abstract 
The envelope glycoprotein of HIV-1 (gp120/gp41) plays an essential role in the 
initial process of viral infection. Three broadly neutralizing antibodies (2F5, 4E10 and 
10E8) bind to the membrane proximal region (MPR, residues 649-683) of HIV-1 gp41, 
which makes the MPR a fascinating template for developing vaccines that can elicit 
antibodies with similar properties. The transmembrane (TM) domain (residues 684-795) 
of gp41 is involved in anchoring the envelope glycoprotein complex in the viral 
membrane but its atomic resolution structure is still unknown. In order to provide a 
structural basis for rational vaccine design, we attempted to crystallize a fusion protein of 
maltose binding protein (MBP) with MPR-TM of gp41 connected by a three-alanine 
linker (MBP-AAA-MPR-TM). The crystal diffracted to 2.5 Å after crystallization 
optimization. Further analysis of the diffraction data indicated that the crystals were 
twinned. The final structure demonstrated that MBP oligomerized as dimers of trimers, 
but the electron density did not extend beyond the linker region. SDS-PAGE and 
MALDI-TOF MS analysis of dissolved crystals confirmed that the crystal contained 
MBP only. As the MBP-AAA-MPR-TM protein is highly purified and is very stable, the 
cleavage may be induced by the process of crystallization. Based on comparison of the 
MBP trimer reported here with published trimeric MBP fusion structures and the fact that 
MBP on its own crystalizes as a monomer, it is indicated that MBP might form such a 
dimer of trimers induced by MPR-TM.  
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4.2 Introduction 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that causes AIDS. 
The envelope glycoprotein (Env) of HIV-1 mediates virion attachment to cells and 
subsequent fusion between viral and cellular membranes (Chan et al., 1997). The HIV-1 
Env consists of a surface subunit, gp120 and a transmembrane subunit, gp41, formed by 
the proteolytic cleavage of a polyprotein precursor, gp160 (Chan and Kim, 1998). Gp120 
and gp41 oligomerize as trimers and are noncovalently associated on the surface of the 
virion (Mao et al., 2012).  
Despite considerable sequence variety, the membrane proximal region (MPR, 
residues 649-683) and transmembrane (TM) domain (residues 684-705) of HIV-1 gp41 
are highly conserved among different subtypes of HIV-1 (Miyauchi et al., 2005; Shang et 
al., 2008; Checkley et al., 2011) and have many important biological functions. 
Transcytosis is one of the initial mucosal transmission pathways of HIV-1, which 
translocate the virus across epithelial cells. Transcytosis is initiated when HIV-1 Env 
binds to the epithelial cell galactosyl ceramide (GalCer) and the minimal region required 
for gp41 to bind GalCer is MPR (Alfsen and Bomsel, 2002). Furthermore, MPR contains 
epitopes for three broadly neutralizing antibodies 2F5 (Purtscher et al., 1994), 4E10 
(Zwick et al., 2001) and 10E8 (Huang et al., 2012). The primary role of gp41 TM domain 
is to anchor the envelope glycoprotein complex in the viral membrane (Yue et al., 2009). 
The HIV-1 Env undergoes dramatic conformational change during membrane 
fusion process. The first state is the pre-fusion state that exists before host-cell encounter 
and receptor binding. The second state is the pre-fusion intermediate state, where gp41 is 
extended and epitopes for broadly neutralizing antibodies are available for antibody 
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binding. The final state is the post-fusion “six-helix bundle” conformation, whose 
structure has been well studied by both X-ray crystallography and NMR (reviewed by 
Merk and Subramaniam (Merk and Subramaniam, 2013)). The structure of a trimeric pre-
fusion form of HIV-1 Env has recently been solved at 3.5 Å by X-ray crystallography 
(Pancera et al., 2014). The HIV-1 Env trimer was captured in a potential pre-fusion 
mature close state by neutralizing antibodies PGT122 (Walker et al., 2011) and 35O22 
(Huang et al., 2014). In the prefusion conformation, the ectodomain of gp41 contains four 
α-helices and one β-strand, which is very different from the post-fusion “six-helix 
bundle” conformation. This pre-fusion conformation of gp41 indicated that structural 
arrangements are needed for fusion activation. However, gp41 in neither pre-fusion nor 
post-fusion conformation could react with the broadly neutralizing antibody 2F5 (Frey et 
al., 2008), whose epitope is on MPR. Accessibility of antibodies to the epitope is of great 
significance for vaccine design. Here, maltose binding protein (MBP) was used as a 
fusion partner to overexpress MPR-TM of gp41. The purified MBP/MPR-TM 
recombinant protein strongly interacts with monoclonal antibodies 2F5 and 4E10 and 
thereby may represent an immunologically relevant conformation mimicking a pre-
hairpin intermediate of gp41. Structural studies of the MBP/MPR-TM recombinant 
protein might be important for the structural-based design of vaccine against HIV-1. 
Crystals from a highly purified and monodisperse solution of the MBP/MPR-TM 
recombinant protein were obtained when MPR-TM was fused to the C-terminus of HIV-1 
gp41 through a three-alanine linker. Crystals of MBP-AAA-MPR-TM diffracted to 2.5 Å 
after crystallization optimization. However, attempts of molecular replacement using 
MBP as the search model failed due to the presence of four-domain twinning. 
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Crystallization and crystallographic analysis of crystals from MBP-AAA-MPR-TM are 
reported here. The final structure demonstrated that MBP oligomerized as dimers of 
trimers, but the electron density did not extend beyond the linker region. Analysis of the 
crystals revealed that they contained MBP only. Comparison of the MBP trimer reported 
here with published trimeric MBP fusion structures indicated that MBP might form such 
a trimer under the influence of MPR-TM.  
4.3 Materials and Methods 
4.3.1 Crystallization and Data Collection 
Expression and purification of MBP-AAA-MPR-TM were carried out as described 
in Chapter 3. Initial crystallization condition of MBP-AAA-MPR-TM was found using 
commercial screens from Hampton Research, Qiagen and Molecular Dimensions. Very 
thin needle crystals (Fig. 4.1A) were obtained using hanging drop vapor diffusion method 
with a 1:1 drop ratio of 2 µl of protein (~15 mg/ml in 20 mM NaCl, 20 mM Tris-HCl, pH 
7.5, 0.015% βDDM) plus 2 µl of reservoir solution (0.1 M Tris-HCl, pH 8.5, 25% PEG 
8000) equilibrated against 800 µl of reservoir solution. However, these needles, which 
diffracted to ~7 Å, were so thin that it was nearly impossible to separate and shoot one of 
them. The diffracted image was overlaps of diffractions from several needle crystals and 
could not be indexed. The initial crystallization condition was further optimized by 
varying the concentration of PEG 8000 and/or adding the CALIXARTM additives 
(Molecular Dimensions). The optimal crystallization condition without additive was as 
follows: 2 µl of protein (~15 mg/ml in 20 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.015% 
βDDM) was mixed with 2 µl of reservoir solution (0.1 M Tris-HCl, pH 8.5, 18 - 25% 
PEG 8000) and equilibrated over 800 µl of reservoir solution. The final conditions with 
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CALIXARTM additives were as follows: 2 µl of protein (~15 mg/ml in 20 mM NaCl, 20 
mM Tris-HCl, pH 7.5, 0.015% βDDM) was mixed with 0.4 µl of CALIXARTM additive 
and 1.6 µl of reservoir solution (0.1 M Tris-HCl, pH 8.5, 18 - 25% PEG 8000). The 
mixture was equilibrated over 800 µl of reservoir solution, which did not contain any 
additive. Crystals were cryoprotected in 0.1 M Tris-HCl, pH 8.5, 30% PEG 8000 for a 
few seconds before being flash frozen in liquid nitrogen. 
Diffraction data were collected at Advanced Light Source (ALS), beamline 821 and 
Advanced Photon Source (APS), Sector 19BM, 23B and 23D. The optimal data set was 
collected using an ADSC 315 CCD detector at ALS beamline 821 at a wavelength of 
0.9999 Å. The distance between the crystal and the detector is 320 mm. Three data sets 
were collected from one crystal. The oscillation per frame is 0.3333° and 360 frames in 
total were collected, which corresponding to 120°.  
4.3.2 Structure Determination and Refinement 
Diffraction images were processed using XDS (Kabsch, 2010) and the integrated 
intensities were scaled using AIMLESS from the CCP4 program suite (Collaborative 
Computational Project, 1994). The phenix.xtriage module of the PHENIX program 
(Adams et al., 2002; Adams et al., 2010) was used to perform the twinning tests of 
collected data. Molecular replacement was carried out with the program Phaser (McCoy 
et al., 2007) or Molrep (Vagin and Teplyakov, 1997) using the structure of an open-form 
MBP (PDB code IFQA) as the search model. The structure was refined using REFMAC 
(Murshudov et al., 1997). All structural figures were produced using PyMol 
(Schrodinger, 2010).  
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4.3.3 SDS-PAGE and MALDI-TOF MS 
Tricine-SDS-PAGE was performed with stacking and resolving gels of 4 % and 8 
%, respectively (Schagger, 2006) and stained by InstantBlue (Expedeon).  
The protocol of MALDI-TOF MS analysis is described in detail previously (Gong 
et al., 2014) and will be only outlined here. Applied Biosystems DE-STR MALDI-TOF 
mass spectrometer was used to accurately measure the molecular weight of the protein. A 
saturated solution in 50% acetonitrile/H2O and 0.1% trifluoroacetic acid (TFA) was used 
as matrix. Spectra were collected in a positive linear mode over a mass range from 15000 
to 90000 Da. Final results represented the average of 10 separate spectra.  
4.4 Results  
4.4.1 Crystallization  
The CALIXARTM Additive Kit was used to optimize the initial crystallization 
condition. It is reported that the CALIXARTM additives promote the crystallization of 
membrane proteins by intercalating between membrane protein molecules and forming 
salt-bridges with positively charged residues on the surface of membrane proteins (Falson 
et al., 2010; Matar-Merheb et al., 2011). With a hydrophilic charged head and a 
hydrophobic alkyl tail of different lengths (Supporting Fig. 4.1), the CALIXARTM 
additives (C4Cn, where n represents the number of carbons in the alkyl tail) have 
detergent-like properties. They form micelles of 5-24 nm with negatively charged head 
outside and hydrophobic tail inside. It is the additive micelles that intercalate between 
membrane protein/detergent complexes and therefore facilitate the crystal formation via 
ionic interactions.  
	   86 
Crystallization optimization trials were carried out with the CALIXARTM additives 
or without any additive. Big needle crystals (Fig. 4.1B) grew after three weeks in 
conditions with every individual CALIXARTM additive from the kit (1 to 10 mM C4C1, 1 
to 10 mM C4C3, 5 to 35 mM C4C5, 5 to 15 C4C7, 0.3 to 3 mM C4C9 and 0.3 to 3 mM 
C4C10, respectively) or without any additive. X-ray diffraction data were collected as 
discussed in Materials and Methods. Crystals with 20% PEG 8000 and 5 mM C4C1 
diffracted to the highest resolution (2.5 Å). 
 
Figure. 4.1. Crystals of MBP-AAA-MPR-TM. (A) Very thin needle crystals of MBP-
AAA-MPR-TM were obtained from initial crystallization screens. (B) Big need crystals 
of MBP-AAA-MPR-TM were obtained after crystallization optimization. 
 
4.4.2 Space group Determination and Structure Solution 
The crystal of MBP-AAA-MPR-TM with additive C4C1 diffracted to 2.5 Å. The 
most likely space group was P62, with unit cell parameters a = 171.93, b = 171.93, c = 
70.08, α = β = 90° and γ = 120°. The structure of MBP was used as the search model for 
molecular replacement. MBP consists of two distinct domains connected by a hinge 
region that move from an open to a closed conformation when the ligand maltose binds to 
the hinge region (Bertz and Rief, 2009). Since no maltose was used during protein 
purification and crystallization, it was assumed that MBP was in the open conformation. 
Therefore, the structure of an open-form MBP (PDB code IFQA) was initially used as the 
search model for molecular replacement. However, only partial solution was obtained in 
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P62 from molecular replacement. A considerable part of the structure could not be built 
and refinement stalled at high R factors. The structure of a closed-form MBP (PDB code 
1FQC) was then used as the search model. However, no improvement was achieved 
compared with using the open-form MBP as the search model. In addition, attempts to 
use the separate domain as search models for molecular replacement also failed.  
By using the phenix.xtriage module of the PHENIX program (Adams et al., 2002; 
Adams et al., 2010), it was determined that the diffraction data were twinned. Strong 
twinning adds extra symmetry to the diffraction data, which can mislead the space-group 
assignment (Barends et al., 2005) and lead to the failure of molecular replacement in the 
wrong space group. Therefore, molecular replacement with an open-form MBP (PDB 
code IFQA) and refinement were repeated using the lower symmetry space groups P3, 
P31 and P32. Molecular replacement in space group P32 using Phaser yielded a partial 
solution of four MBP monomers in one asymmetric unit, which had reasonable geometry 
and no clashes. However, there was still an appreciable part of the structure that could not 
be built.  
The most probable content of the asymmetric unit, estimated using Matthews from 
the CCP4 program suite (Collaborative Computational Project, 1994), contains 5-6 
molecules with a solvent content between 50.67 and 40.80 under the assumption that the 
true space group is P32. The P32-model with four MBP monomers obtained using Phaser 
previously was refined using Refmac (Murshudov et al., 1997). The fifth MBP monomer 
was positioned using Molrep (Vagin and Teplyakov, 1997) and refined. This step was 
repeated to position the sixth MBP monomer. Please note that the amplitude based twin 
refinement was essential to be used during refinement; otherwise the position of the fifth 
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MBP monomer was not correctly assigned. The final P32-model with six MBP monomers 
(dimer of trimers) underwent several rounds of refinement with global NCS, no NCS and 
local NCS successively. The final crystallographic data statistics are summarized in Table 
4.1. 
4.4.3 Space Group Validation with Zanuda 
The space-group assignment was further validated by Zanuda, a program that was 
developed by Lebedev and Isupov to automate the validation of space group assignment, 
especially in presence of pseudosymmetry or twinning (Lebedev and Isupov, 2014). A 
P31-model with six MBP monomers was prepared using similar strategies of preparing 
the P32-model. The P31-model was finally refined to an R factor of 0.283 and an Rfree of 
0.317 and submitted to Zanuda. As a result, the input P31-model is converted into P32 
model, which conforms the correct space group assignment of P32. 
4.5 Discussion 
4.5.1 Overview Structure 
The structure was refined to 2.49 Å in space group P32 with good refinement 
statistics (Table 4.1). The overall final R factor and Rfree were 0.159 and 0.194 
respectively. Each asymmetric unit (ASU) contains 6 monomers of MBP in the open 
conformation, which form two layers of trimers (or dimer of trimers, top view in Fig. 
4.2A). These two trimers are oriented in different direction (front and back trimer in Fig. 
4.2A) forming a “sandwich” with neighbor trimers. The C-termini of MBP are at the 
center of the trimer, which are indicated by red asterisks (Fig. 4.2A). However, there was 
no electron density visible beyond Ala381, which is the third residue of the three-alanine 
linker between MBP and MPR-TM (Fig. 4.3). There might be two reasons: First, the 
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target protein MPR-TM could be unstructured in the crystal, because the MPR-TM region 
could be flexible. Second, the target protein could be cleaved or degraded during or after 
the process of crystallization.  
Table 4.1. Data collection and refinement statistics 
Data collection 
Resolution (Å) 43.88 - 2.49 
Wavelength used (Å) 0.9999 
Space group P32 
Unit cell parameters 
 a, b, c (Å) 171.93, 171.93, 70.08 
α, β, γ (deg) 90, 90, 120 
No. of reflections 252285 
No. of unique reflections 68170 
Rmerge (%) 12.1 (52.8) 
I/σ(I) 7.7 (1.7) 
Redundancy 3.7 (2.2) 
Completeness (%) 84.4 (68.8) 
CC (1/2) 0.986 (0.375) 
No. of molecules per ASU 6 
Solvent content (%) 39.72 
Refinement 
Resolution range  (Å) 43.88 - 2.49 
R factor  0.159 (0.194) 
Rfree 0.194 (0.285) 
Rmsd for bond length  (Å) 0.014 
Rmsd for bond angles (deg) 1.55 
 
Crystals of MBP-AAA-MPR-TM were dissolved and analyzed by SDS-PAGE and 
MALDI-TOF MS to determine if MPR-TM is still present in the crystal. The protein 
from dissolved crystals migrates faster than the purified fusion protein MBP-AAA-MPR-
TM prior to crystallization (Fig. 4.4A). In addition, the purified fusion protein MBP-
AAA-MPR-TM prior to crystallization showed a peak of 48750 Da in the Mass spectrum 
(Fig. 4.4B), which agreed well with its theoretical molecular weight (48761 Da).  The 
protein from dissolved crystals showed a peak of 41097 – 41675 Da in Mass spectrum 
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(Fig. 4.4B), which indicated that dissolved crystals contained MBP only, whose 
molecular weight is 41694 Da.  
 
Figure 4.2. Cartoon diagrams of the six monomers of MBP in one asymmetric unit. (A) 
Top view. The six MBP molecules form two layers of trimmers, which are oriented in 
different directions. The C-termini of MBP are at the center of each trimer, which are 
indicated by red asterisks. (B) Side view of the six MBP molecules (left). A sliced side 
view (right) is presented in order to show the C-termini of MBP. 
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Figure 4.3. The C-terminus of the model with a 2Fo – Fc electron density map. Residues 
371 – 381 of one of the six molecules are shown in stick representation. There is no 
electron density beyond Ala381, which is the third residue of the three-alanine linker 
between MBP and MPR-TM. 
 
 
 
Figure 4.4. Analysis of dissolved crystals. (A) SDS-PAGE analysis. Lane 1: ladder; lane 
2: purified MBP-AAA-MPR-TM fusion protein before crystallization; lane 3: protein 
from dissolved crystal. (B) MALDI MS analysis of MBP-AAA-MPR-TM before 
crystallization. (C) MALDI-TOF MS analysis of the protein from dissolved crystals. 
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4.5.2 The Molecular Interface and Packing Interactions 
The six MBP molecules in the ASU are actually identical, with an RMSD less 
than 0.199 Å between corresponding Cα positions. Protein contacts are observed and 
highlighted in Fig 4.5. The interface area between each monomer inside the trimer of the 
same layer is 566.4 Å2 (Fig. 4.5A). The interface area between each monomer from the 
two layers of trimers is 289.4 Å2 (Fig. 4.5B). The interfacing residues are listed in 
Supporting Table 4.1 and Supporting Table 4.2.  
 
Figure 4.5. Molecular interface. (A) Molecular interface between each monomer inside 
the trimer of the same layer in sphere representation (left) and ribbon representation 
(right). Interface residues are highlighted in red. (B) Molecular interface between each 
monomer from the two layers of trimers in sphere representation (left) and ribbon 
representation (right). Interface residues are highlighted in red. 
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MBP is a monomer by itself (Spurlino et al., 1991). It forms different oligomers 
depending on the target proteins it fused with. It is reported that MBP exists as a trimer 
(Kobe et al., 1999; Song et al., 2003; Bethea et al., 2008; Kim et al., 2009; Lamb et al., 
2011; Du et al., 2013), a dimer (Liu et al., 2001; Zhang et al., 2011) or a monomer (Ke et 
al., 2012; Patrick et al., 2013) in the crystal structure when it fused with different target 
proteins.  
The MPR-TM (residues 649 – 705) is part of the envelope glycoprotein of HIV-1 
gp41 (residues 512 - 856), which forms a trimeric spike on the surface of the HIV-1 
virion (Buzon et al., 2010; Shi et al., 2010). The sequence of HIV-1 gp41 contains a 4-3 
hydrophobic repeat, with hydrophobic amino acids spaced every four and then every 
three residues apart, which is characteristic of forming coiled coil (Fass and Kim, 1995; 
Lu et al., 1995). Trimerization of gp41 is one of the mechanisms that HIV-1 has evolved 
to escape antibody binding. Vulnerable epitopes are less exposed on gp41-trimer than on 
the individual monomeric subunit (Burton et al., 2004).  
Interestingly, the arrangement of the MBP monomers inside the MBP-trimer is 
very similar to some of the published MBP fusion protein trimers (Fig. 4.6). Further 
analysis of the trimeric MBP fusion proteins indicated that the target proteins contain a 4-
3 hydrophobic repeat (coiled coil motif) (Kobe et al., 1999; Lamb et al., 2011; Du et al., 
2013), which is characteristic for HIV-1 gp41 as well (Lu et al., 1995). Figure 4.6B 
shows the superposition of the structure of our MBP (green) on the structure of MBP-
gp21 chimera (shown in blue, which actually contains MBP and the ectodomain of gp21) 
(Kobe et al., 1999). Gp21 is the transmembrane protein of human T cell leukemia virus 
type 1 (HTLV-1), which is a retrovirus. Figure 4.6C shows the superposition of the 
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structure of MBP (green) on the structure of MBP-gp30 chimera (represented in pink, 
which is actually composed of MBP and the ectodomain of gp30) (Lamb et al., 2011). 
Gp30 is the transmembrane protein of bovine leukemia virus (BLV-1). BLV-1 is also a 
retrovirus. Figure 4.6D shows the superposition of the structure of MBP (green) on the 
structure of MBP-CC chimera (yellow) (Du et al., 2013). CC stands for the coiled coil 
motif of the minichromosome maintenance protein 10 (Mcm10). The MBP-gp21, MBP-
gp30 and MBP-CC chimera trimers all have a mushroom shape, with the coiled coil motif 
(ectodomain of gp21, ectodomain of gp30 and coiled coil motif of Mcm10 respectively) 
forming the stalk and the MBP trimer constituting the head. The MBP-trimer represented 
here (Fig. 4.6A) only contains the head of the mushroom. Although SDS-PAGE and 
MALDI-TOF MS analysis indicated that dissolved crystals contained MBP only (Fig. 
4.4), it is possible that MBP forms a trimer under the effect of MPR-TM, which is part of 
the trimeric envelope glycoprotein of HIV-1 gp41. 
However, the crystal packings of our trimeric MBP and other trimeric MBP 
fusion proteins are different (Fig. 4.7). The front trimers and back trimers of our MBP are 
alternatively superimposed on each other (Fig. 4.7A). The crystal packings of MBP-gp21 
ectodomain chimera (Fig. 4.7B) and MBP-gp30 ectodomain chimera (Fig. 4.7C) are 
similar: the “stalks” of the “mushrooms” are pointed at one direction and the “heads” of 
the “mushrooms” are shifted among different layers. In the case of MBP-CC chimera, the 
“heads” of the “mushrooms” are shifted among different layers but the “stalks” of the 
“mushrooms” are pointed at opposite directions. 
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Figure 4.6. Comparison of trimeric MBP with other trimeric MBP fusion proteins. (A) 
MBP (only the front trimer is shown for clear representation). (B-D) Superposition of the 
structure of MBP on the structure of (B) MBP-gp21 ectodomain chimera (PDB ID 
1MG1) (Kobe et al., 1999), (C) MBP-gp30 ectodomain chimera (PDB ID 2XZ3) (Lamb 
et al., 2011) and (D) MBP-CC chimera (PDB ID 4JBZ) (Du et al., 2013), respectively. 
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Figure 4.7. The crystal packing of trimeric MBP and other MBP fusion protein trimers. 
(A) MBP. The front trimers are demonstrated in green and back trimers are shown in red. 
(B) MBP-gp21 ectodomain chimera (PDB ID 1MG1) (Kobe et al., 1999). (C) MBP-gp30 
ectodomain chimera (PDB ID 2XZ3) (Lamb et al., 2011). (D) MBP-CC chimera (4JBZ) 
(Du et al., 2013). 
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4.6 Conclusion 
Crystallization of MBP-AAA-MPR-TM was optimized by adding the CALIXARTM 
additive. Crystals with additive C4C1 diffracted to the highest resolution. The final 
structure was refined to 2.49 Å in space group P32 with R factor of 0.159 and Rfree of 
0.194, respectively. Each asymmetric unit (ASU) contains 6 monomers of MBP in the 
open conformation, which form two layers of trimers rotated in opposite orientations. 
However, there is no electron density beyond Ala381, which is the third residue of the 
three-alanine linker between MBP and MPR-TM. The crystals were dissolved and 
analyzed by SDS-PAGE and MALDI-TOF MS. The result demonstrated that the crystals 
contained MBP only. MPR-TM might be cleaved during or after the process of 
crystallization. Comparison of the structures of published trimeric MBP fusion proteins 
indicated that they have a mushroom shape, with the coiled coil motif (ectodomain of 
gp21, ectodomain of gp30 and coiled coil motif of Mcm10 respectively) forming the stalk 
and the trimeric MBP moieties constituting the head. The MBP trimer represented here 
has a very similar “mushroom head” but does not contain the “mushroom stalk”. It is 
possible that MBP forms a trimer under the effect of MPR-TM, which is part of the 
trimeric envelope glycoprotein of HIV-1 gp41. 
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4.7 Supporting Information 
4.7.1 Supporting Figures 
 
Supporting Fig. 4.1. Chemical structure of the CALIXARTM additives, C4Cn (Matar-
Merheb et al., 2011).  
 
4.7.2 Supporting Tables 
Number Source atoms Target atoms Distance (Å) 
1 D/ 366(GLN). / CA  [ C] E/  63(ALA). / O  [ O] 3.46 
2 D/ 367(THR). / N     [ N] E/  63(ALA). / O  [ O] 2.85 
3 D/ 367(THR). / OG1[ O] E/  63(ALA). / O  [ O] 3.36 
4 D/ 367(THR). / CG2 [ C] E/  65(GLY). / CA [ C] 3.39 
5 D/ 373(ALA). / CB   [ C] E/  84(SER). / C  [ C] 3.46 
6 D/ 373(ALA). / CB   [ C]	   E/  84(SER). / O  [ O] 3.35 
7 D/ 369(ASP). / CB [ C] E/  85(GLY). / O  [ O] 3.37 
Supporting Table 4.1. Interfacing residues between each monomer inside the trimer of 
the same layer.  	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Number Source atoms Target atoms Distance (Å) 
1 A/ 220(ASP). / OD2[ O] B/  52(ASP). / N  [ N] 3.12 
2 A/ 222(SER). / OG [ O] B/  52(ASP). / CG [ C] 3.11 
3 A/ 222(SER). / OG [ O] B/  52(ASP). / OD1[ O] 2.48 
4 A/ 220(ASP). / CB [ C] B/  52(ASP). / OD2[ O] 3.42 
5 A/ 220(ASP). / CG [ C] B/  52(ASP). / OD2[ O] 3.32 
6 A/ 221(TYR). / N  [ N] B/  52(ASP). / OD2[ O] 3.23 
7 A/ 222(SER). / N  [ N] B/  52(ASP). / OD2[ O] 3.02 
8 A/ 222(SER). / OG [ O] B/  52(ASP). / OD2[ O] 2.97 
9 A/ 218(ASP). / OD1[ O] B/  57(LYS). / NZ [ N] 3.36 
10 A/  57(LYS). / NZ [ N] B/ 218(ASP). / OD1[ O] 3.41 
11 A/  52(ASP). / OD2[ O] B/ 220(ASP). / CG [ C] 3.50 
12 A/  52(ASP). / N  [ N] B/ 220(ASP). / OD2[ O] 3.24 
13 52(ASP). / OD2[ O] B/ 222(SER). / N  [ N] 3.08 
14 52(ASP). / OD2[ O] B/ 222(SER). / CB [ C] 3.42 
15 A/  52(ASP). / CG [ C] B/ 222(SER). / OG [ O] 3.06 
16 A/  52(ASP). / OD2[ O] B/ 222(SER). / OG [ O] 2.68 
17 A/  52(ASP). / OD1[ O] B/ 222(SER). / OG [ O] 2.59 
 
Supporting Table 4.2. Interfacing residues between each monomer from the two layers 
of trimers.  
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CHAPTER 5 
SUMMARY AND OUTLOOK 
5.1 Summary 
Mistic, a Bacillus subtilis integral membrane protein, could be used as a fusion 
partner to overexpress the MPR-TM of HIV-1 gp41. The expression level of MPR-TM 
was improved by fusion to the C-terminus of Mistic, yielding ~1 mg of pure MPR-TM 
protein per liter. The fusion partner Mistic was removed for final crystallization. The 
isolated MPR-TM protein was biophysically characterized and is a monodisperse 
candidate for crystallization. However, no crystal with diffraction quality was obtained 
after extensive crystallization screens. It may be due to the highly hydrophobic property 
of MPR-TM and/or lack of crystal contacts between MPR-TM molecules. Significantly, 
the purified MPR-TM protein reacts strongly with the broadly neutralizing Abs 2F5 and 
4E10 with nanomolar to subnanomolar affinities. Our result indicated that the isolated 
MPR-TM protein might be in a pre-hairpin intermediate state, in which epitopes for 
mAbs are available for antibody binding (Frey et al., 2008). Although no crystal with 
diffraction quality was obtained, the protocol of purifying monodisperse MPR-TM was 
established. The purified MPR-TM protein could be used for other purposes instead of 
crystallization, for instance, structural studies of MPR-TM by NMR.    
A novel construct was designed to overexpress MPR-TM as a maltose binding 
protein (MBP) fusion. MBP not only improves the solubility and expression level of 
MPR-TM, but may also provide a large hydrophilic interaction surface for formation of 
crystal lattice contacts thereby facilitating crystal formation. About 60 mg of MBP/MPR-
TM recombinant protein was obtained from 1 liter of cell culture. Crystals of MBP/MPR-
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TM recombinant protein could not be obtained when MBP and MPR-TM were separated 
by a 42 aa-long linker but were obtained after changing the linker to three alanine 
residues.  
The crystal of MBP-AAA-MPR-TM diffracted to 2.5 Å after crystallization 
optimization by adding the CALIXARTM additive. Crystals with additive C4C1 diffracted 
to the highest resolution. Further analysis of the diffraction data indicated that the crystal 
is twinned. The final structure was refined to 2.49 Å in space group P32 with R factor of 
0.164 and Rfree of 0.196, respectively. Each ASU contains 6 monomers of MBP in the 
open conformation, which form two layers of trimers rotated in opposite orientations. 
However, the electron density did not extend beyond the linker region. It is later figured 
out that the crystal contained MBP only. The MPR-TM of gp41 might be cleaved by 
protease impurities from protein purification or degrade because of instability during or 
after the process of crystallization. Comparison of the MBP trimer reported here with 
published trimeric MBP fusion structures indicated that MBP might form such a trimeric 
conformation under the effect of MPR-TM. 
In general, MBP could be used as a potential fusion partner to improve the 
expression level of membrane proteins. The linker of MBP fusion protein plays a crucial 
role in crystallization. MBP together with the three-alanine linker is a useful tool to study 
the structure of membrane proteins.  
5.2 Outlook 
5.2.1 The Structure of Gp41 in Prehairpin Intermediate State is Highly Demanded 
The HIV-1 gp41 undergoes at least three distinct conformational states during 
membrane fusion process: the pre-fusion conformation, an extended prehairpin 
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intermediate and the post-fusion “six-helix bundle” conformation. The structure of gp41 
in post-fusion conformation has been well studied since 1997 (Chan et al., 1997; 
Weissenhorn et al., 1997) by both X-ray crystallography and NMR (reviewed in ref. 
(Merk and Subramaniam, 2013)). The structure of HIV-1 Env in pre-fusion conformation 
has recently been solved at 3.5 Å by X-ray crystallography (Pancera et al., 2014). 
However, gp41 in neither pre-fusion nor post-fusion conformation could react with the 
broadly neutralizing antibody 2F5, whose epitope is on MPR. It is very important to 
study the structure of gp41 in the prehairpin intermediate state, in which epitopes for 
mAbs are available for antibody binding (Frey et al., 2008). Structural studies of gp41 in 
pre-fusion, prehairpin intermediate and post-fusion conformations will help us understand 
the viral and cellular membrane fusion process and design structural-based vaccines 
against HIV-1. 
Interestingly, none of the structures of gp41 solved by X-ray crystallography or 
NMR included the TM domain of gp41. In this thesis, the isolated MPR-TM protein 
removed from Mistic-MPR-TM fusion and the MBP/MPR-TM recombinant protein react 
strongly with the broadly neutralizing Abs 2F5 and 4E10. Our results provide further 
experimental evidence of the importance of the transmembrane domain of gp41 to 
preserve the immunological signature of the membrane proximal region of gp41 
(Montero et al., 2012), probably mimicking in a pre-hairpin intermediate. It also 
demonstrates the need to remove the heptad repeat regions. Our study will give some 
hints for future construct design to study the intermediate state of gp41.  
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5.2.2 Crystallization with Antibodies 
The final structure demonstrated that MBP oligomerized as trimers, but the electron 
density did not extend beyond the linker region. MPR-TM might degrade because of 
instability during or after the process of crystallization. Many proteins have been 
crystallized with in complex with high affinity antibody fragments (Acharya et al., 2014; 
Pancera et al., 2014; Robin et al., 2014; Rudicell et al., 2014; Wright et al., 2014). Co-
crystallization with antibody is believed to increase the probability of crystallization by 
providing a large hydrophilic contact for initial crystallization formation and/or limiting 
the conformational flexibility of solvent exposed loop regions (Hunte and Michel, 2002; 
Lam et al., 2009). The broadly neutralizing mAbs 2F5 and 4E10 displayed high binding 
affinity to purified MPR-TM protein and MBP/MPR-TM recombinant protein. These 
antibodies could be used for co-crystallization with MPR-TM or MBP-AAA-MPR-TM. 
5.2.3 Structural Studies of the C-terminal Tail of Gp41  
As the only viral protein exposed on the virion surface, the Env of gp41 has been 
the primary target for structural studies and vaccine development. Much research has 
been focused on gp120 and the ectodomain of gp41. In contrast, the C-terminal tail (CTT, 
residues 706-856) of gp41, which is approximately 150 aa long, has received relatively 
little attention. The CCT of gp41 is involved in many important functions, such as Env 
trafficking and virion incorporation (Freed and Martin, 1996), virion maturation (Jiang 
and Aiken, 2007), Env endocytosis (Byland et al., 2007), modulation of the overall Env 
structure (Edwards et al., 2002) and so on. In spite of functional significance, the atomic 
level structure of CTT is still unknown. 
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Early topogenesis studies classified gp41 as a type I membrane protein, including 
an N-terminal extracellular domain, a single α-helical membrane-spanning domain 
(MSD) and a long cytoplasmic CTT (Haffar et al., 1988). An alternative model has been 
proposed by Hollier and Dimmock (Hollier and Dimmock, 2005) with three membrane-
spanning β-sheets based on the fact that the Kennedy epitope (KE) (Kennedy et al., 
1986), which is located in the cytoplasmic CTT according to the single MSD model, is 
extracellularly exposed under some circumstances. KE (residues 735-752) is a strongly 
reactive peptide located in the CTT identified in earlier studies attempting to generate 
antibodies recognizing the precursor Env (gp160) (Kennedy et al., 1986). Interestingly, 
the sera against the KE strongly neutralized virus, indicating the extracellular exposure of 
the epitope, because antibodies cannot cross intact lipid membranes. The two proposed 
MSD models are shown in Fig. 5.1 (Steckbeck et al., 2010). 
 
Fig. 5.1. Proposed topology models for HIV-1 gp41 CTT (Steckbeck et al., 2010). (A) 
Traditional CTT model with one membrane-spanning α-helix. (B) Alternative CTT 
model with multiple MSD segments proposed by Holllier and Dimmonck (Hollier and 
Dimmock, 2005). This model proposes three membrane-spanning β-sheets and an 
extracellular localization of the KE, which is highlighted in yellow. LLP: lentivirus lytic 
peptide. 
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Additionally, the MBP with three-alanine linker studied in this thesis could be used 
as a helpful tool to study the structure of gp41 CCT.  
5.2.4 Utilize Eukaryotic Expression Systems 
HIV-1 is a human virus and it replicates itself in the infected human cells. Although 
E. coli is the most frequently used expression system for prokaryotic and eukaryotic 
membrane proteins (Gordon et al., 2008), E. coli’s ability to perform posttranslational 
modifications is poor and the posttranslational modifications are usually essential for 
proper folding, targeting and function (Blum et al., 2000). Therefore, it is worth trying to 
express the membrane protein of HIV-1 in eukaryotic expression systems.  
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